

Daiichi Sankyo, Inc. US Research Payments January 1, 2015 through December 31, 2015

		Principal Investigator /	Principal Investigator /	City of DI (1 and	State of PI /	
Payee	Study Name	Lead Researcher	Lead Researcher	City of PI / Lead Researcher	Lead	Total
ABIGAIL R NEIMAN MD	Treatment of Pain Associated With Fibromyalgia	Last Name NEIMAN	First Name ABIGAIL	HOUSTON	Researcher TX	\$5,000.00
ABRAMSON CNCR CENTER PENN STATE	Study of Tivantinib in Subjects With Inoperable	DAMJANOV	NEVENA	PHILADELPHIA	PA	\$780.99
ABRAMSON CNCR CENTER PENN STATE	TC00001950	DAMJANOV	NEVENA	PHILADELPHIA	PA	\$81.90
ACTIVMED PRACTICES & RESEARCH INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in	COLE	BERTRAND	SOMERSWORTH	NH	\$15,094.16
ACTIVMED PRACTICES & RESEARCH INC.		SHAY	MARC	AMESBURY	MA	\$3,324.46
ADAMS, GEORGE	Edoxaban in Peripheral Arterial Disease ePAD					\$81.48
ADLY THEBAUD MD PA		THEBAUD	ADLY	SANFORD	FL	\$5,000.00
ADVANCED CLINICAL RESEARCH ASSOCIATION	An Open-Label Extension Study of DS-5565 for 52 Weeks in		AHTARAM	PLANO	TX	\$61,441.42
ADVANCED CLINICAL RESEARCH ASSOCIATION AFFILIATED CARDIOLOGISTS OF AZ	Treatment of Pain Associated With Fibromyalgia	KHAN BASHIR	AHTARAM FARAN	PLANO	TX AZ	\$192,812.50 \$9,738.39
AGAIBY, JOHN	Edoxaban vs. Warfarin in Subjects Undergoing An Open-Label Extension Study of DS-5565 for 52 Weeks in	AGAIBY	JOHN	PHOENIX KENOSHA	WI	\$9,738.39
AGAIBY, JOHN	Treatment of Pain Associated With Fibromyalgia	AGAIBY	JOHN	KENOSHA	WI	\$38,440.35
ALAM, MOHAMMED	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ALAM	MOHAMMED	OAK BROOK	IL	\$2,500.00
ALBUQUERQUE NEUROSCIENCE	An Open-Label Extension Study of DS-5565 for 52 Weeks in		GLENN	ALBUQUERQUE	NM	\$18,581.51
ALBUQUERQUE NEUROSCIENCE	Treatment of Pain Associated With Fibromyalgia	DEMPSEY	GLENN	ALBUQUERQUE	NM	\$49,760.89
ALEXANDER, STANLEY	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ALEXANDER	STANLEY	ARCADIA	CA	\$5,000.00
ALFTINE, CHRISTOPHER	An Open-Label Extension Study of DS-5565 for 52 Weeks in		CHRISTOPHER	MEDFORD	OR	\$32,923.15
ALFTINE, CHRISTOPHER	Treatment of Pain Associated With Fibromyalgia	ALFTINE	CHRISTOPHER	MEDFORD	OR	\$142,719.18
ALI, MOHAMED	Treatment of Pain Associated With Fibromyalgia	ALI	MOUSTAFA	FALL RIVER	MA	\$118,769.98
ALI, MOHAMED	Treatment of Pain Associated With Fibromyalgia	ALKALI	AREF	DOCUECTED		\$5,740.00
AL-KALI, AREF ALLIANCE CLINICAL RESEARCH LLC	(QuANTUM-R): An Open-label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in	CONNOR	GORDON	ROCHESTER BIRMINGHAM	MN AL	\$16,697.94 \$50,726.33
ALLIANCE CLINICAL RESEARCH LLC	An Open-Label Extension Study of DS-5565 for 52 Weeks in		PETER	MOUNTAIN BRK	AL	\$13,286.28
ALTEA RESEARCH INSTITUTE	Treatment of Pain Associated With Fibromyalgia	KUNOVAC	JELENA	OCEANSIDE	CA	\$31,993.17
ALTOONA CENTER FOR CLINICAL RESEARCH PC		KIVITZ	ALAN	DUNCANSVILLE	PA	\$3,500.00
AMATRUDA, JOHN	12-Week Study of DS-8500a in Subjects With Type 2					\$10,750.00
AMATRUDA, JOHN	Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1					\$6,815.11
AMATRUDA, JOHN	PLX3397 Phase 3 Study for Pigmented Villonodular				L	\$123.48
AMERICAN MEDICAL RESEARCH		ALAM	MOHAMMED	OAK BROOK	IL	\$2,500.00
ANDERSEN, JAMES	Treatment of Pain Associated With Fibromyalgia	ANDERSEN	JAMES	LAKELAND	FL	\$90,894.60
ANN & ROBERT H LURIE CHILD HOSPITAL	Phase 1 Pediatric PKPD Study	MARINO	BRADLEY	CINCINNATI	ОН	\$12,100.00
ANNEX, BRIAN	Edoxaban in Peripheral Arterial Disease ePAD					\$2,119.94
ANSEL, GARY APTER, JEFFREY	Edoxaban in Peripheral Arterial Disease ePAD An Open-Label Extension Study of DS-5565 for 52 Weeks in	ADTER	JEFFREY	PRINCETON	NJ	\$8,351.82 \$3,750.00
APTER, JEFFREY	Treatment of Pain Associated With Fibromyalgia	APTER	JEFFREY	PRINCETON	NJ	\$9,993.00
ARCH HEALTH PARTNERS	Edoxaban vs. Warfarin in Subjects Undergoing	SAWHNEY	NAVINDER	ESCONDIDO	CA	\$8,063.80
ARELLANO, MARTHA	(QuANTUM-R): An Open-label Study of Quizartinib	ARELLANO	MARTHA	ATLANTA	GA	\$18,638.59
ARIZONA ARTHRITIS/RHEUMATOLOGY		TESSER	JOHN	PHOENIX	AZ	\$3,500.00
ARIZONA RESEARCH CENTER PHNX ORTHOPEDICS	An Open-Label Extension Study of DS-5565 for 52 Weeks in	TABER	LOUISE	PHOENIX	AZ	\$8,829.00
ARIZONA RESEARCH CENTER PHNX ORTHOPEDICS	Treatment of Pain Associated With Fibromyalgia	TABER	LOUISE	PHOENIX	AZ	\$124,222.48
ARKANSAS CHILDREN'S HOSPITAL	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	THRAILKILL	KATHRYN	LITTLE ROCK	AR	\$1,320.00
ARMAS, EDDIE	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ARMAS	EDDIE	SOUTH MIAMI	FL	\$1,000.00
ARMAS, EDDIE	Treatment of Pain Associated With Fibromyalgia	ARMAS ARORA	EDDIE SAMIR	SOUTH MIAMI POWELL	FL OH	\$177,318.09 \$17,637.20
ARORA, SAMIR ARROWHEAD HEALTH CENTERS	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	JOHNSTON	JANICE	GLENDALE	AZ	\$13,863.08
ARROWHEAD HEALTH CENTERS	reachent of rain associated with horomyaiga	JOHNSTON	JANICE	GLENDALE	AZ	\$4,000.00
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	MEHRA	PURVI	SAN DIEGO	CA	\$12,730.84
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia	MEHRA	PURVI	SAN DIEGO	CA	\$77,850.32
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH		MEHRA	PURVI	SAN DIEGO	CA	\$3,500.00
ARTHRITIS TREATMENT CENTER	An Open-Label Extension Study of DS-5565 for 52 Weeks in	WEI	NATHAN	FREDERICK	MD	\$5,968.17
ARTHRITIS TREATMENT CENTER	Treatment of Pain Associated With Fibromyalgia	WEI	NATHAN	FREDERICK	MD	\$19,076.97
ASSOCIATION IN ONCOLOGY AND HEMATOLOGY	Study of Patritumab in Combination With Study of	GANDHI	JITENDRA	CHATTANOOGA	TN	\$18,950.05
ATLANTA CENTER FOR MEDICAL RESEARCH INC. ATLANTA INSTITUTE OF MEDICINE & RESEARCH INC.	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	WYATT SAMBUNARIS	DAVID ANGELO	ATLANTA ATLANTA	GA GA	\$100,149.69 \$54,297.40
AUSTIN CENTER FOR CLINICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia	Laurent	Aziz	Austin	TX	\$4,000.00
AUSTIN HEART	DU176b-E-U210	KARHA	JUHANA	AUSTIN	TX	\$5,822.00
AYENI, OLUROPO	Edoxaban Cancer VTE	AYENI	OLUROPO	JONESBORO	GA	\$10,000.00
BABER, RIAZ	An Open-Label Extension Study of DS-5565 for 52 Weeks in		RIAZ	NAPERVILLE	IL	\$10,385.21
BABER, RIAZ	Treatment of Pain Associated With Fibromyalgia	BABER	RIAZ	NAPERVILLE	IL	\$53,549.38
BAER, MARIA	(QuANTUM-R): An Open-label Study of Quizartinib	BAER	MARIA	BALTIMORE	MD	\$8,785.70
BANYAN GROUP INC. D/B/A CLINVEST & HEADACHE CARE		CADY	ROGER	SPRINGFIELD	MO	\$6,000.00
BASTIAN, BORIS	Transferrance of Datio Associate district Still 1	DATEMAN	LUCINDA			\$105.40
BATEMAN, LUCINDA BAYSTATE MEDICAL CENTER	Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study	BATEMAN	LUCINDA HOLLEY	SALT LAKE CITY SPRINGFIELD	UT MA	\$46,594.71 \$13,369.97
BELLEVUE HOSPITAL CENTER	TC00001950	WU	JENNIFER	BROOKLYN	NY	\$13,369.97
BEND MEMORIAL CLINIC	Study of Patritumab in Combination With Study of	SCHMIDT	WILLIAM	BEND	OR	\$444.41
BERGER, BRIAN	Study of DS-7080a for the Treatment of Neovascular Age-				1	\$1,374.82
BERK, MARTIN	Global Study to Assess the Safety and Effectiveness of					\$3,339.97
BETH ISRAEL DEACONNESS HOSPITAL	DU176b-D-U311	ZWICKER	JEFFREY	BOSTON	MA	\$57.90
BETH ISRAEL DEACONNESS HOSPITAL	Study of Tivantinib in Subjects With Inoperable	MIKSAD	REBECCA	BOSTON	MA	\$55,923.21
BHATIA, PERMINDER	An Open-Label Extension Study of DS-5565 for 52 Weeks in		PERMINDER	FRESNO	CA	\$13,078.16
BHATIA, PERMINDER	Treatment of Pain Associated With Fibromyalgia	BHATIA	PERMINDER	FRESNO	CA	\$39,307.42
BHUCHAR, SUBODH	Treatment of Pain Associated With Fibromyalgia	BHUCHAR	SUBODH	SUGAR LAND	TX AZ	\$4,000.00
BILTMORE CARDIOLOGY BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC	Edoxaban vs. Warfarin in Subjects Undergoing Study of Erlotinib With or Without Investigational Drug (U3	BAHU PIPERDI	MARWAN BILAL	PHOENIX WORCESTER	AZ MA	\$107.40 \$2,865.52
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC	Study of Eriotinib with or without investigational Drug (U3 Study of Tivantinib in Subjects With Inoperable	SCHWARTZ	JONATHAN	PORTLAND	OR	\$2,865.52 \$38,364.69
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC	staay of mantimo in subjects with moperable	TROCK	DAVID	DANBURY	СТ	\$4,025.00
BIOPHARMA INFORMATIC INC.		KRISHNASWAMY	KANNAPPAN	SEALY	тх	\$9,500.00
BIOPHARMA INFORMATIC INC.		NEIMAN	ABIGAIL	HOUSTON	TX	\$4,500.00
BIXBY, DALE	(QuANTUM-R): An Open-label Study of Quizartinib	BIXBY	DALE	ANN ARBOR	MI	\$23,241.50
BLAIR ORTHOPEDICS	Treatment of Pain Associated With Fibromyalgia	BOZAK	DAVID	ALTOONA	PA	\$11,611.58
BLAIR ORTHOPEDICS		BARRANCO	ELIZABETH	PONCE	PR	\$3,000.00
BLAIR ORTHOPEDICS BLAIR ORTHOPEDICS		BOZAK	DAVID	ALTOONA	PA	\$2,125.00
		LATORRE	AGUSTIN	SOUTH MIAMI	FL	\$2,125.00

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator Lead Researcher First Name	/ City of PI / Lead Researcher	State of PI / Lead Researcher	Total
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	Study to Evaluate the Efficacy, Safety, and	SURDELL	DANIEL	OMAHA	NE	\$3,485.00
BORDERS, JAMES	An Open-Label Extension Study of DS-5565 for 52 Weeks in		JAMES	LEXINGTON	KY	\$27,317.74
BORDERS, JAMES BOWDEN, ROY	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	BORDERS BOWDEN	JAMES ROY	LEXINGTON CHARLESTON	KY WV	\$76,604.94 \$14,923.44
BRETTON, ELIZABETH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	BRETTON	ELIZABETH	ALBUQUERQUE	NM	\$15,647.80
BRETTON, ELIZABETH	Treatment of Pain Associated With Fibromyalgia	BRETTON	ELIZABETH	ALBUQUERQUE	NM	\$52,781.45
BREVARD CARDIOVASCULAR RESEARCH ASSOCIATION INC.	Edoxaban vs. Warfarin in Subjects Undergoing	SHEIKH	KHALID	COCOA BEACH	FL	\$8,664.66
BREWER, RANDALL BREWER, RANDALL	Safety Study of DS-5565 for Treatment of Fibromyalgia					\$5,000.00 \$777.33
BRIGHAM & WOMAN'S HOSPITAL	Safety Study of DS-5565 for Treatment of Fibromyalgia Electronic Alerts for Stroke Prevention in Patients With	GOLDHABER	SAMUEL	BOSTON	МА	\$103,850.00
BRIGHAM & WOMEN'S HOSPITAL	DU176b-D-U311	ZWICKER	JEFFREY	BOSTON	MA	\$57.90
BUCHANAN, PATRICIA	An Open-Label Extension Study of DS-5565 for 52 Weeks in	BUCHANAN	PATRICIA	EUGENE	OR	\$23,098.56
BURGHER, ABRAM	Treatment of Pain Associated With Fibromyalgia	BURGHER	ABRAM	PEORIA	AZ	\$1,404.00
BUTLER HEALTH SYSTEM BHS CARDIOVASCULAR BUTLER MEDICAL PROVIDERS	Edoxaban vs. Warfarin in Subjects Undergoing Edoxaban vs. Warfarin in Subjects Undergoing	RAO RAO	SUNDER SUNDER	CRANBERRY TWP CRANBERRY TWP	PA PA	\$62.65 \$136.00
BUTLER MEDICAL PROVIDERS	Edoxaban vs. Warfarin in Subjects Undergoing	WEISS	ROBERT	AUBURN	ME	\$228.00
BYSTRITSKY, ALEXANDER	Treatment of Pain Associated With Fibromyalgia	BYSTRITSKY	ALEXANDER	LOS ANGELES	CA	\$5,627.61
CABRERA, RONIEL	Study of Tivantinib in Subjects With Inoperable					\$1,480.05
CADY, ROGER	Treatment of Pain Associated With Fibromyalgia	CADY	ROGER	SPRINGFIELD	MO	\$25,540.55
CALIFORNIA MEDICAL RESEARCH ASSOCIATION INC. CANCER CARE ASSOCIATION OF YORK	Study of Erlotinib With or Without Investigational Drug (U3	PATAK EFIOM-EKAHA	RAM DANIEL	NORTHRIDGE YORK	CA PA	\$4,000.00 \$1,750.64
CAPITAL AREA RESEARCH LLC	DU176b-E-U210	NADAR	VENKATESH	CAMP HILL	PA	\$7,407.00
CAPITAL AREA RESEARCH LLC	Edoxaban vs. Warfarin in Subjects Undergoing	NADAR	VENKATESH	CAMP HILL	PA	\$11,416.97
CAPITAL AREA RESEARCH LLC	TC00002989	NADAR	VENKATESH	CAMP HILL	PA	\$26.85
CAPRIO, SONIA	Colesevelam Pediatric Type 2 Diabetes Mellitus Study			CT1115000		\$2,783.08
CARDIOLOGY ASSOCIATION OF FAIRFIELD COUNTY PC CARDIOLOGY ASSOCIATION RESEARCH COMPANY	Edoxaban vs. Warfarin in Subjects Undergoing Edoxaban vs. Warfarin in Subjects Undergoing	HEIMAN HENDERSON	DAVID	STAMFORD DAYTONA BEACH	CT FL	\$9,678.12 \$25,783.29
CARDIOLOGY ASSOCIATION RESEARCH COMPANY	DU176b-E-U210	MENDELSOHN	FARRELL	BIRMINGHAM	AL	\$25,783.29 \$2,994.00
CARDIOLOGY PHYSICIANS PA	Edoxaban vs. Warfarin in Subjects Undergoing	CLAY	ANTHONY	NEWARK	DE	\$11,074.85
CARDIOLOGY PHYSICIANS PA	Edoxaban vs. Warfarin in Subjects Undergoing	CRENSHAW	JAMES	JACKSON	TN	\$53.70
CARDIOLOGY PHYSICIANS PA	TC00002989	CLAY	ANTHONY	NEWARK	DE	\$17.90
CARDIOLOGY RESEARCH ASSOCIATION CARDIOVASCULAR MEDICAL GROUP	Edoxaban vs. Warfarin in Subjects Undergoing DU176b-E-U210	HENDERSON DOHAD	DAVID	DAYTONA BEACH BEVERLY HILLS	FL CA	\$278.45 \$2,402.40
CARDIOVASCULAR RESEARCH INSTITUTE OF DALLAS	Edoxaban vs. Warfarin in Subjects Undergoing	BERK	MARTIN	DALLAS	ТХ	\$3,226.85
CARL AND EDYTH LINDNER CENTER FOR RESEARCH AND	An Open-Label Extension Study of DS-5565 for 52 Weeks in		DEAN	CINCINNATI	ОН	\$9,566.42
CARMAN RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in		NATHAN	SMYRNA	GA	\$18,633.42
CARMAN RESEARCH	Treatment of Pain Associated With Fibromyalgia	SHAPIRA	NATHAN	SMYRNA	GA	\$56,850.42
CARMAN RESEARCH CEDARS - SINAI MEDICAL CENTER	Study of Tivantinib in Subjects With Inoperable	SHAPIRA IMAGAWA	NATHAN DAVID	SMYRNA ORANGE	GA CA	\$5,500.00 \$276.24
CEDARS - SINAI MEDICAL CENTER	Study of Tivantinib in Subjects With Inoperable	MILES	STEVEN	WEST HOLLYWOOD	CA	\$15,010.83
CENTER FOR ADVANCED RESEARCH EXCELLENCE	Edoxaban vs. Warfarin in Subjects Undergoing	AGGARWAL	RAHUL	JUPITER	FL	\$7,885.92
CENTER FOR BIOMEDICAL RSRCH	Study of Patritumab in Combination With Study of	DEVORE	RUSSELL	KNOXVILLE	TN	\$21,130.76
CENTER FOR PHRMCTCL RSRCH		ERVIN	JOHN	KANSAS CITY	MO	\$7,886.80
CERVANTES, JAMES CHAYKIN, LOUIS	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	CERVANTES CHAYKIN	JAMES LOUIS	BELLEVUE LAKEWOOD RANCH	NE FL	\$4,000.00
CHICAGO RESEARCH CENTER INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in	PLYLER	BRETT	CHICAGO	IL.	\$92,289.65
CHICAGO RESEARCH CENTER INC.	Treatment of Pain Associated With Fibromyalgia	PLYLER	BRETT	CHICAGO	IL	\$333,488.62
CHICAGO RESEARCH CENTER INC.		PLYLER	BRETT	CHICAGO	IL	\$4,000.00
CHILDREN'S HOSPITAL BOSTON	Phase 1 Pediatric PKPD Study	TRENOR	CAMERON	BOSTON	MA	\$16,000.00
CHILDREN'S HOSPITAL LOS ANGELES CHILDREN'S HOSPITAL LOS ANGELES	Colesevelam Pediatric Type 2 Diabetes Mellitus Study Phase 1 Pediatric PKPD Study	FISHER YOUNG	LYNDA GUY	LOS ANGELES LOS ANGELES	CA CA	\$74,016.71 \$21,492.50
CHILDREN'S HOSPITAL OF WISCONSIN	Phase 1 Pediatric PKPD Study	NIEBLER	ROBERT	MILWAUKEE	WI	\$8,677.00
CHILDREN'S MEDICAL CENTE	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	LOPEZ	XIMENA	DALLAS	ТХ	\$11,083.50
CHILDRENS MERCY HOSPITAL	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	UGRASBUL	FIGEN	KANSAS CITY	MO	\$1,179.00
CHOC CHILDREN'S HOSPITAL CHOI, DANIEL	Phase 1 Pediatric PKPD Study An Open-Label Extension Study of DS-5565 for 52 Weeks in	MAHAJERIN CHOI	ARASH DANIEL	ORANGE SCOTTSDALE	CA AZ	\$11,250.00 \$3,735.00
CHOI, DANIEL CHOI, DANIEL	Treatment of Pain Associated With Fibromyalgia	CHOI	DANIEL	SCOTTSDALE	AZ	\$23,765.64
CHOI, STEVE	An Open-Label Extension Study of DS-5565 for 52 Weeks in		STEVE	DAYTON	ОН	\$33,918.75
CHOI, STEVE	Treatment of Pain Associated With Fibromyalgia	CHOI	STEVE	DAYTON	ОН	\$127,083.04
CHOI, STEVE	Treatment of Pain Associated With Fibromyalgia					\$1,559.00
CIFUENTES, ENRIQUE	Treatment of Pain Associated With Fibromyalgia	CIFUENTES KOCZYWAS	ENRIQUE	TEMPE	AZ	\$41,843.70
CITY OF HOPE NATIONAL MEDICAL CENTER CITY OF HOPE NATIONAL MEDICAL CENTER	DS2248-A-U101 DS3032-A-U102	ROSENTHAL	MARIANNA JOSEPH	DUARTE DUARTE	CA CA	\$9,034.69 \$15,792.10
CITY OF HOPE NATIONAL MEDICAL CENTER	Study of Patritumab in Combination With Study of	KOCZYWAS	MARIANNA	DUARTE	CA	\$19,310.73
CLARK, GORDON	Treatment of Pain Associated With Fibromyalgia	CLARK	GORDON	SHAWNEE	KS	\$5,126.70
CLAXTON, DAVID	(QuANTUM-R): An Open-label Study of Quizartinib	CLAXTON	DAVID	HERSHEY	PA	\$25,430.34
CLEVELAND SLEEP RESEARCH CENTER CLEVELAND SLEEP RESEARCH CENTER	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	AHMED AHMED	MANSOOR MANSOOR	CLEVELAND CLEVELAND	ОН ОН	\$2,000.00 \$48,162.35
CLEVELAND SLEEP RESEARCH CENTER CLINICAL NEUROSCIENCE SOLUTIONS INC.	reament of Pain Associated With Fibromyaigia	HARPER	LINDA	ORLANDO	FL	\$48,162.35 \$51,587.56
CLINICAL NEUROSCIENCE SOLUTIONS INC.		JOSHI	NANDITA	ST AUGUSTINE	FL	\$12,284.39
CLINICAL PHARMACOLOGY OF MIAMI INC.	AC220-016	LASSETER	KENNETH	HIALEAH	FL	\$48,004.94
CLINICAL RESEARCH ADVANTAGE INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in		LADAN	PLANO	ТХ	\$18,323.96
CLINICAL RESEARCH ADVANTAGE INC. CLINICAL RESEARCH ADVANTAGE INC.	Treatment of Pain Associated With Fibromyalgia	ALLAW GEISBERG	MOHAMMED	NEWBURGH	IN SC	\$12,233.88 \$5,086.84
CLINICAL RESEARCH ADVANTAGE INC.	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	RIFFER	HARRY ERNIE	ANDERSON PHOENIX	AZ	\$23,148.02
CLINICAL RESEARCH ADVANTAGE INC.		ALLAW	MOHAMMED	NEWBURGH	IN	\$5,000.00
CLINICAL RESEARCH ADVANTAGE INC.		RIFFER	ERNIE	PHOENIX	AZ	\$5,000.00
CLINICAL RESEARCH ALLIANCE INC.	TIVANTINIB	ARENA	FRANCIS	LAKE SUCCESS	NY	\$5,290.00
CLINICAL RESEARCH CENTER LLC	An Open Label Extension Study of DS ESSE for 53 March	SAHAGIAN	ARIS	ROYAL PALM BEACH	FL	\$35,053.20
CLINICAL RESEARCH OF CENTRAL FLORIDA CLINICAL RESEARCH OF CENTRAL FLORIDA	An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in		MICHAEL Robinson	PLANT CITY Lakeland	FL	\$16,825.06 \$52,188.45
CLINICAL RESEARCH OF CENTRAL FLORIDA	Treatment of Pain Associated With Fibromyalgia	GIMNESS	MICHAEL	PLANT CITY	FL	\$43,974.62
CLINICAL RESEARCH OF CENTRAL FLORIDA	Treatment of Pain Associated With Fibromyalgia	Koilpillai	Robinson	Lakeland	FL	\$246,992.17
CLINICAL RESEARCH OF WEST FLORIDA INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in		ELIAS	SAFETY HARBOR	FL	\$82,145.96
CLINICAL RESEARCH PARTNERS LLC	Transmont of Dain Associated With Filmannelain	DANIEL	JEROME	RICHMOND	VA	\$10,000.00
CLINICAL RESEARCH SOURCE INC. CLINICAL TRIAL INVESTIGATORS	Treatment of Pain Associated With Fibromyalgia	KALB SELAM	ROBERT JEAN LOUIS	TOLEDO TUSTIN	OH CA	\$26,764.88 \$3,700.00
CLINICAL TRIAL INVESTIGATORS		FORTE	VINCENT	MONROE	LA	\$3,800.00
CLINICAL TRIALS OF AMERICA		GUTIERREZ STONE	JESUS	ORLANDO	FL	\$3,250.00
CLINICAL TRIALS OF AMERICA INC.	Treatment of Pain Associated With Fibromyalgia	FORTE	VINCENT	MONROE	LA	\$65,715.52
CLINICAL TRIALS OF AMERICA INC.		FORTE	VINCENT	MONROE	LA	\$3,800.00
CLINICAL TRIALS OF TEXAS	DU176b-E-U210	FRITCHER	SETH	SAN ANTONIO	TX	\$14,374.00 \$4,590.00
CNS CLINICAL RESEARCH GROUP COASTAL CARDIOLOGY CONSULTANTS PA	Edoxaban vs. Warfarin in Subjects Undergoing	KASS KOVACH	ETHAN TODD	CORAL SPRINGS CLEARWATER	FL	\$2,918.63

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
COASTAL CLINICAL RESEARCH INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in	STUDDARD	HARRY	MOBILE	AL	\$4,500.00
COASTAL CLINICAL RESEARCH INC.	Treatment of Pain Associated With Fibromyalgia	STUDDARD	HARRY	MOBILE	AL	\$85,010.28
COASTAL CONNECTICUT RESEARCH LLC	Treatment of Pain Associated With Fibromyalgia	MCDERMOTT	EDWARD	NEW LONDON	СТ	\$11,273.00
COASTAL CONNECTICUT RESEARCH LLC		MCDERMOTT	EDWARD	NEW LONDON	СТ	\$3,250.00
CODDING, CHRISTINE CODDING, CHRISTINE	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CODDING CODDING	CHRISTINE	OKLAHOMA CITY OKLAHOMA CITY	OK OK	\$4,000.00 \$48,738.99
COHEN, STANLEY	DS2626 Compound A	CODDING	CHRISTINE	OREAHOWA CITY	OK	\$5,465.88
COHEN-GADOL, SHARIAR	An Open-Label Extension Study of DS-5565 for 52 Weeks in	COHEN GADOL	SHARIAR	THOUSAND OAKS	CA	\$165,747.34
COLE, BERTRAND	Treatment of Pain Associated With Fibromyalgia	COLE	BERTRAND	SOMERSWORTH	NH	\$54,469.41
COLLABORATIVE NEUROSCIENCE NETWORK INC.		GLICK	IRA	STANFORD	CA	\$1,812.50
COLLABORATIVE NEUROSCIENCE NETWORK INC.		GOENJIAN	ARMEN	LONG BEACH	CA	\$8,000.00
COLLINS, ROBERT COLORADO NEUROLOGY INSTITUTE	(QuANTUM-R): An Open-label Study of Quizartinib Study to Evaluate the Efficacy, Safety, and	COLLINS HEBB	ROBERT ADAM	DALLAS ENGLEWOOD	TX CO	\$13,494.00 \$2,011.26
COLORADO NEUROLOGY INSTITUTE	Study to Evaluate the Efficacy, Safety, and	West	George	Englewood	со	\$1,750.00
COLUMBIA UNIVERSITY MEDICAL CENTER	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	LEIBEL	NATASHA	NEW YORK	NY	\$26,059.10
COMMUNITY RESEARCH MANAGEMENT ASSOCIATION	Treatment of Pain Associated With Fibromyalgia	POLAND	STEPHEN	CINCINNATI	ОН	\$22,705.38
COMPASS RESEARCH LLC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	RADBILL	KEVIN	WINTER PARK	FL	\$123,001.68
COMPASS RESEARCH NORTH LLC COMPLETE CARDIOLOGY CARE	An Open-Label Extension Study of DS-5565 for 52 Weeks in		DAVID	MANSFIELD DAYTONA BEACH	OH FL	\$20,000.64 \$347.94
COMPREHENSIVE CANCER CENTERS OF NEVADA	Edoxaban vs. Warfarin in Subjects Undergoing Study of Patritumab in Combination With Study of	HENDERSON BRAITEH	FADI	LAS VEGAS	NV	\$72,600.56
CONDEMI, JOHN	An Open-Label Extension Study of DS-5565 for 52 Weeks in	CONDEMI	JOHN	ROCHESTER	NY	\$7,203.08
CONDEMI, JOHN	An Open-Label Extension Study of DS-5565 for 52 Weeks in	CONDENN	10111	nochesten		\$3,000.00
CONDEMI, JOHN	Treatment of Pain Associated With Fibromyalgia	CONDEMI	JOHN	ROCHESTER	NY	\$37,034.23
CONNECTICUT CHILDREN'S MEDICAL CENTER	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	PHULWANI	PRIYA	HARTFORD	СТ	\$11,534.00
CONRAD, MARYANN	An Open-Label Extension Study of DS-5565 for 52 Weeks in	COLVARD	MARYANN	PORTLAND	OR	\$41,641.20
	An Open-Label Extension Study of DS-5565 for 52 Weeks in	CONRAD	VICKI	EDMOND	OK	\$11,299.54
CONRAD, VICKI COOPER HEALTH SYSTEM	Treatment of Pain Associated With Fibromyalgia PLX108-10	CONRAD LERMAN	VICKI NATI	EDMOND CAMDEN	OK NJ	\$99,306.40 \$44,214.25
COOPER HEALTH SYSTEM	PLX108-10 Study to Evaluate the Efficacy, Safety, and	WANG	JU-LIN	CAMDEN	NJ	\$44,214.25 \$8,051.57
COOPER UNIVERSITY HEALTH CARE	PLX108-10	LERMAN	NATI	CAMDEN	NJ	\$503.40
COPELAND, KENNETH	Colesevelam Pediatric Type 2 Diabetes Mellitus Study					\$4,382.22
CORDERO, ABNER	Treatment of Pain Associated With Fibromyalgia	CORDERO	ABNER	TIFFIN	ОН	\$138,807.45
CORTES, JORGE	(QuANTUM-R): An Open-label Study of Quizartinib	CORTES-FRANCO	JORGE	HOUSTON	тх	\$6,823.50
COUNTY OF SANTA CLARA DBA SANTA CLARA VALLEY	Study to Evaluate the Efficacy, Safety, and	CREW	JAMES	SAN JOSE	CA	\$6,131.33
CPMC RESEARCH INSTITUTE CRAIG HOSPITAL	TC00002960 Study to Evaluate the Efficacy, Safety, and	BARON LAMMERTSE	ARI DANIEL	SAN FRANCISCO ENGLEWOOD	CA CO	\$63.00 \$12,377.50
CUTLER, ANDREW	Treatment of Pain Associated With Fibromyalgia	CUTLER	ANDREW	UNIVERSITY PARK	FL	\$12,377.50 \$23,906.12
D' SOUZA, BERNADETTE	An Open-Label Extension Study of DS-5565 for 52 Weeks in	DSOUZA	BERNADETTE	DAYTON	ОН	\$10.957.50
D' SOUZA, BERNADETTE	Treatment of Pain Associated With Fibromyalgia	DSOUZA	BERNADETTE	DAYTON	ОН	\$106,914.32
DAILEY, GEORGE	12-Week Study of DS-8500a in Subjects With Type 2					\$630.00
DAMJANOV, NEVENA	Study of Tivantinib in Subjects With Inoperable					\$1,788.24
DANA - FARBER COMMUNITY CNCR CARE	PLX108-10	WAGNER	ANDREW	BOSTON	MA	\$27,625.00
DANBURY HOSPITAL	Treatment of Pain Associated With Fibromyalgia	TROCK	DAVID	DANBURY	СТ	\$4,000.00
DANIEL, JEROME DAVIDSON, EVELYNE	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	DANIEL DAVIDSON	JEROME EVELYNE	RICHMOND KNOXVILLE	VA TN	\$84,658.93 \$38,300.50
DAVIDSON, EVELYNE	Treatment of Pain Associated With Fibromyalgia	DAVIDSON	EVELYNE	KNOXVILLE	TN	\$256,447.29
DE FRANCISCO, DON	An Open-Label Extension Study of DS-5565 for 52 Weeks in	DE FRANCISCO	DON	NEWPORT BEACH	CA	\$8,073.00
DE FRANCISCO, DON	Treatment of Pain Associated With Fibromyalgia	DE FRANCISCO	DON	NEWPORT BEACH	CA	\$18,995.40
DEACONESS CLINIC	Study of Erlotinib With or Without Investigational Drug (U3	AHMED	MAQBOOL	EVANSVILLE	IN	\$1,393.92
DELA LLANA, ALEXANDER	· · ·	DELA LLANA	ALEXANDER	EVANSVILLE	IN	\$4,300.08
DELA LLANA, ALEXANDER DELA LLANA, ALEXANDER	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	DELA LLANA	ALEXANDER	EVANSVILLE	IN	\$15,783.60 \$156,159.75
DELTA WAVES		ROBERSON	KENT	COLORADO SPRINGS	со	\$30,373.20
DELTA WAVES	Treatment of Pain Associated With Fibromyalgia	ROBERSON	KENT	COLORADO SPRINGS	co	\$131,237.65
DENVER HEALTH AND HOSPITAL AUTHORITY	Study to Evaluate the Efficacy, Safety, and	LADLEY OBRIEN	SUSAN	DENVER	CO	\$1,372.53
DESERT VALLEY RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDERSON	DONALD	BANNING	CA	\$83,652.10
DESERT VALLEY RESEARCH	Treatment of Pain Associated With Fibromyalgia	ANDERSON	DONALD	BANNING	CA	\$150,246.57
DESERT VALLEY RESEARCH DIABLO CLINICAL RESEARCH INC.	An Open Label Extension Study of DS EEGE for E2 Weeks in	ANDERSON	DONALD	BANNING ALAMO	CA	\$31,669.60
DIABLO CLINICAL RESEARCH INC. DIABLO CLINICAL RESEARCH INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CHUCK	LEONARD	ALAIVIO	C.4	ćo 004 37
DIABLO CLINICAL RESEARCH INC.	incutinent of Fain Associated with Fibromyaigia		LEONARD	ALAMO	CA	\$9,084.37 \$75,172,50
DIAZ, JORGE		CHUCK	LEONARD LEONARD	ALAMO ALAMO	CA CA CA	\$9,084.37 \$75,172.50 \$5,000.00
	Treatment of Pain Associated With Fibromyalgia				CA	\$75,172.50 \$5,000.00 \$22,738.43
DIAZ, JORGE	Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ	LEONARD JORGE	ALAMO HIALEAH	CA CA FL	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54
DIBUONO, MARK	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	CHUCK DIAZ DIBUONO	LEONARD JORGE MARK	ALAMO HIALEAH STATEN ISLAND	CA CA FL NY	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87
DIBUONO, MARK DIBUONO, MARK	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO	LEONARD JORGE MARK MARK	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND	CA CA FL NY NY	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79
DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA	LEONARD JORGE MARK MARK MICHAEL	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA	CA CA FL NY NY NY	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20
DIBUONO, MARK DIBUONO, MARK	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIPERSIO	LEONARD JORGE MARK MARK	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND	CA CA FL NY NY	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79
DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIGROSO, JOHN	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of Quizartinib	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIPERSIO	LEONARD JORGE MARK MARK MICHAEL JOHN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS	CA CA FL NY NY NY MO	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10
DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIPERSIO, JOHN DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIPERSIO BOX	LEONARD JORGE MARK MARK MICHAEL JOHN JANE	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE	CA CA FL NY NY NY MO NC	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65
DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIPERSIO, JOHN DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL OL DIAA	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIPERSIO BOX BOX BOX BOX	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE	CA CA FL NY NY MO NC NC NC NC	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00
DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIPERSIO, JOHN DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DOCTORS RESEARCH INSTITUTE INC.	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age-	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DI GIOVANNA DI PERSIO BOX BOX BOX BOX GONZALEZ	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE MISAEL	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES	CA CA FL NY NY NY NC NC NC FL	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIJOCANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DJL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DI GIOVANNA DIPERSIO BOX BOX BOX BOX BOX GONZALEZ DODD	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JANE JANE JOHN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON	CA CA FL NY NY MO NC NC NC FL MS	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,474.12
DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIFERSIO, JOHN DIL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DI GIOVANNA DI PERSIO BOX BOX BOX BOX GONZALEZ	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE MISAEL	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES	CA CA FL NY NY NY NC NC NC FL	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,474.12 \$73,066.41
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIJOCANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DJL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DI GIOVANNA DIPERSIO BOX BOX BOX GONZALEZ DODD DODD DODD	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JANE JANE JOHN JOHN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON	CA CA FL NY NY MO NC NC FL MS MS	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,474.12
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIPERSIO, JOHN DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN DODD, JOHN DODD, JOHN DOMEK, DAVID DOWES, DAVID DOUST, MATTHEW	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIFERSIO BOX BOX BOX GONZALEZ DODD DODD DODD DOMEK DOWST	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE JANE JOHN JOHN JOHN DAVID DAVID DAVID MATTHEW	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY PHOENIX	CA CA FL V NY NY MO NC NC NC FL MS OK OK AZ	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$60,204.60
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIFERSIO, JOHN DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN DODDE, JOHN DOMEK, DAVID DOMEK, DAVID DOUST, MATTHEW DRUG STUDIES AMERICA	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DI GIOVANNA DI GIOVANNA BOX BOX BOX BOX GONZALEZ DODD DODD DOMEK DOMEK	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JOHN JOHN JOHN DAVID DAVID	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY	СА СА FL NY NY MO NC NC NC NC FL MS MS OK OK	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$60,204.60 \$38,230.50
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGOVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN DODD, JOHN DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUSBERKE, EKIK	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIFERSIO BOX BOX BOX GONZALEZ DODD DODD DODD DOMEK DOWST	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE JANE JOHN JOHN JOHN DAVID DAVID DAVID MATTHEW	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY PHOENIX	CA CA FL V NY NY MO NC NC NC FL MS OK OK AZ	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$9290.00 \$22,515.64 \$27,474.12 \$73,066.458.00 \$10,152.00 \$60,204.60 \$38,230.50 \$3,690.69
DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIGROVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH MIL DODD, JOHN DODD, JOHN DODD, JOHN DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUST, MATTHEW DRUG STUDIES AMERICA DUBBERKE, ERIK DUBBERKE, ERIK	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIFERSIO BOX BOX BOX BOX GONZALEZ DODD DODD DODD DOMEK DOUST TARK	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JANE JANE JAN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA	CA CA FL NY NY MO NC NC NC NC FL MS OK OK OK AZ GA	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$60,204.60 \$38,230.50 \$3,690.69 \$26,93
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DODD, JOHN DODDD, JOHN DODDD, JOHN DOMEK, DAVID DOUST, MATTHEW DRUG STUDIES AMERICA DUBBERKE, ERIK DUBFFY, JOHN	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of DS-S565 for 52 Weeks in	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIFERSIO BOX BOX BOX BOX GONZALEZ DODD DODD DODD DOMEK DOUST TARK	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE JANE JOHN JOHN JOHN DAVID DAVID DAVID MATTHEW	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY PHOENIX	CA CA FL V NY NY MO NC NC NC FL MS OK OK AZ	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$50,204.60 \$38,230.50 \$3,690.69 \$22,549.4584.58
DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIGROVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH MIL DODD, JOHN DODD, JOHN DODD, JOHN DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUST, MATTHEW DRUG STUDIES AMERICA DUBBERKE, ERIK DUBBERKE, ERIK	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIFERSIO BOX BOX BOX BOX GONZALEZ DODD DODD DODD DOMEK DOUST TARK	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JANE JANE JAN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA	CA CA FL NY NY MO NC NC NC NC FL MS OK OK OK AZ GA	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$229.00 \$22,515.64 \$27,747.12 \$73,066.41 \$6,588.00 \$10,152.00 \$60,204.60 \$38,230.50 \$3,690.69 \$26,33
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGOVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH NSTITUTE INC. DODD, JOHN DODD, JOHN DODMEK, DAVID DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUBBERKE, ERIK DUBBERKE, ERIK DUFFY, JOHN	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in (QuANTUM-R): an Open-label Study of Quizartinib An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of DS-S565 for 52 Weeks in Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study Of DS-S565 for 52 Weeks in Safety Study of DS-S565 for Teatment of Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DIBUONO DIGUVANNA DIPERSIO BOX BOX GONZALEZ DODD DODD DODD DOMEK DOMEK DOMEK DOUST TARK DUFFY DUFFY	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JOHN JOHN JOHN DAVID DAVID DAVID MATTHEW MARVIN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA TUSTIN	СА СА FL NY NY MO NC NC NC NC FL MS MS OK OK AZ GA CA	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$292.900 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$60,204.60 \$38,230.50 \$33,690.69 \$33,690.69 \$26,533 \$64,584.58 \$4,250.00
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGOVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN DODD, JOHN DODD, JOHN DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUSE RESEARCH RESEARCH DUBBERKE, ERIK DUBBERKE, ERIK DUBFY, JOHN DUFFY, JOHN DUFFY, JOHN DUKE FIBROMYALGIA	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DIBUONO DIGUVANNA DIPERSIO BOX BOX BOX GONZALEZ DODD DODD DODD DOMEK DOMEK DOMEK DOUST TARK DUFFY DUFFY PATKAR PATKAR PATKAR	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JOHN JOHN DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID JOHN ASTHVIN ASHWIN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA TUSTIN CARY CARY	СА СА СА FL NY NY MO NC NC NC FL MS MS OK OK OK QK AZ CA CA CA NC	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$9,421.10 \$37,563.23 \$12,454.65 \$292.90 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$60,204.60 \$38,230.50 \$33,690.69 \$28,230.50 \$33,690.69 \$26,533 \$544,584.58 \$4,250.00 \$189,621.45 \$4,250.00 \$189,621.45 \$4,250.00 \$189,621.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590.45 \$3,590.45\$3,590
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH MICHAEL DODD, JOHN DODD, JOHN DODD, JOHN DOMEK, DAVID DOMEK, DAVID DUST, MATTHEW DRUG STUDIES AMERICA DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBFY, JOHN DUFFY, JOHN DUFFY, JOHN DUFFY, JOHN DUKE FIBROMYALGIA DUKE FIBROMYALGIA	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in IQuANTUM-R): An Open-label Study of OS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DI GIOVANNA DI GIOVANNA BOX BOX BOX BOX BOX BOX GONZALEZ DODD DODD DODD DODD DODD DOMEK DOUST TARK DUFFY PATKAR PATKAR HERNANDEZ	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JANE JOHN DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID JOHN MATTHEW MARVIN JOHN ASHWIN ASHWIN ADRIAN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CARLOTTE JACKSON JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA TUSTIN CARY CARY CARY DURHAM	СА СА СА FL NY NY MO NC NC NC MS OK OK OK OK QK AZ GA CA CA NC NC	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$37,563.23 \$12,454.65 \$292.00 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$60,204.60 \$38,230.50 \$36,60.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,660.69 \$3,551.00 \$33,954.54 \$788,551.00
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIFRSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN DODD, JOHN DODD, JOHN DODDS, MATTHEW DOUST, MATTHEW DOUST, MATTHEW DUBBERKE, ERIK DUBFEY, JOHN DUFFY, JOHN DUFFY STP	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of CAUSTON An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIFERSIO BOX BOX BOX GONZALEZ DODD DODD DODD DOMEK DOMEK DOMEK DOUST TARK DUFFY PATKAR HERNANDEZ GRANGER	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JOHN JOHN JOHN DAVID DAVID DAVID MATTHEW MARVIN JOHN JOHN ASHWIN ASHWIN ASHWIN ASHWIN ASHWIN CHRISTOPHER	ALAMO HIALEAH FEADUREAN ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON JACKSON JACKSON JACKSON TUSTIN CARY CARY CARY DURHAM DURHAM	CA CA CA FL NY NY MO NC NC NC NC CA CA CA CA CA CA CA CA CA CA CA CA NC NC	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,7474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$50,204.60 \$38,230.50 \$38,230.50 \$38,230.50 \$38,245.84.58 \$4,250.00 \$189,621.45 \$9,500.00 \$33,954.551.00 \$278,000.00
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGOVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN DODD, JOHN DODD, JOHN DODMEK, DAVID DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBFY, JOHN DUFFY, JOHN DUFFY, JOHN DUFFY JOHN DUFF JIONMALGIA DUKE FIBROMYALGIA DUKE UNIVERSITY DUKE UNIVERSITY	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of PS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Addressing Real-world Anticoagulant Management Issues Clinical Trial to Improve Treatment With Blood Thinners in EVOLVE-AF PCI	CHUCK DIAZ DIBUONO DIBUONO DIBUONO DIGUVANNA DIPERSIO BOX BOX BOX BOX GONZALEZ DODD DODD DODD DODD DOMEK DOMEK DOWST TARK DUFFY PATKAR PATKAR PATKAR PATKAR PATKAR FRANADEZ GRANGER ROE	LEONARD JORGE MARK MARK MARK MARK JOHN JANE JANE JANE JANE JANE JANE JOHN JOHN DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID CHN JOHN ARTHEW	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA TUSTIN TUSTIN TUSTIN CARY CARY CARY DURHAM DURHAM DURHAM	СА СА СА СА FL NY NY MO NC NC FL MS OK OK OK OK CA CA CA CA NC NC NC NC NC NC NC NC NS OK NS OK NS OK NS OK NS OK NS OK NS NS OK NS NS NS NS NS NS NS NS NS NS	\$75,172.50 \$5,000.00 \$22,738.43 \$12,033.54 \$38,467.79 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$292.90 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$60,204.60 \$38,230.50 \$33,690.69 \$33,690.69 \$33,690.69 \$26,533 \$54,5484.58 \$9,550.00 \$33,954.54 \$788,551.00 \$238,950.00 \$238,950.00 \$238,950.00 \$238,950.00 \$238,950.00 \$238,950.00 \$238,950.00 \$238,950.00 \$24,053,224,55
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGOVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN DODD, JOHN DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBFY, JOHN DUFFY, JOHN DUFFY JOHN DUFFY SITY DUKE UNIVERSITY DUKE UNIVERSITY DUKE UNIVERSITY	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in IQuANTUM-R): An Open-label Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Biomyalgia Treatment of Pain Associated With Biomyalgia Treatment of Pain Associated With Biomyalgia Colesian Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Biomyalgia Addressing Real-world Anticoagulant Management Issues Clinical Trial to Improve Treatment With Blood Thinners in EVOLVE-AF PCI	CHUCK DIAZ DIBUONO DIBUONO DIBUONO DI GIOVANNA DI GIOVANNA BOX BOX BOX BOX BOX BOX BOX GONZALEZ DODD DODD DODD DODD DODD DOMEK DOUST TARK DUFFY PATKAR PATKAR PATKAR HERNANDEZ GRANGER ROE GRANGER	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JANE JOHN DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID JOHN ASHWIN ASHWIN ASHWIN ADRIAN CHRISTOPHER	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA TUSTIN CARY CARY CUSTIN CARY DURHAM DURHAM DURHAM DURHAM DURHAM	СА СА СА FL NY NY MO NC NC NC MS MS OK OK OK QK AZ CA CA CA NC NC NC NC NC NC NC NC NC NC	\$75,172,50 \$5,000,0 \$22,738,43 \$12,033,54 \$9,229,87 \$38,467,79 \$36,223,20 \$7,793,10 \$9,421,10 \$37,563,23 \$12,454,65 \$929,00 \$22,515,64 \$27,474,12 \$73,066,41 \$6,588,00 \$10,152,00 \$60,204,60 \$38,230,50 \$3,690,69 \$26,93 \$64,584,58 \$4,250,00 \$38,961,45 \$9,500,00 \$33,954,54 \$78,551,00 \$278,000,00 \$278,000,00 \$21,05,322,45 \$40,000,00
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGOVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH INSTITUTE INC. DODD, JOHN DODD, JOHN DODD, JOHN DODMEK, DAVID DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBFY, JOHN DUFFY, JOHN DUFFY, JOHN DUFFY JOHN DUFF JIONMALGIA DUKE FIBROMYALGIA DUKE UNIVERSITY DUKE UNIVERSITY	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of PS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Addressing Real-world Anticoagulant Management Issues Clinical Trial to Improve Treatment With Blood Thinners in EVOLVE-AF PCI	CHUCK DIAZ DIBUONO DIBUONO DIBUONO DIGUVANNA DIPERSIO BOX BOX BOX BOX GONZALEZ DODD DODD DODD DODD DOMEK DOMEK DOWST TARK DUFFY PATKAR PATKAR PATKAR PATKAR PATKAR FRANADEZ GRANGER ROE	LEONARD JORGE MARK MARK MARK MARK JOHN JANE JANE JANE JANE JANE JANE JOHN JOHN DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID CHN JOHN ARTHEW	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA TUSTIN TUSTIN TUSTIN CARY CARY CARY DURHAM DURHAM DURHAM	СА СА СА СА FL NY NY MO NC NC FL MS OK OK OK OK CA CA CA CA NC NC NC NC NC NC NC NC NS OK NS OK NS OK NS OK NS OK NS OK NS NS OK NS NS NS NS NS NS NS NS NS NS	\$75,172.50 \$5,000.0 \$22,738.43 \$12,033.54 \$9,229.87 \$38,467.79 \$36,223.20 \$7,793.10 \$9,421.10 \$37,563.23 \$12,454.65 \$929.00 \$22,515.64 \$27,474.12 \$73,066.41 \$6,588.00 \$10,152.00 \$30,690.69 \$3,690.69 \$3,690.69 \$3,690.69 \$3,690.69 \$3,690.69 \$4,250.00 \$33,954.54 \$95,500.00 \$33,954.54
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIGROVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DJL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH MILCL DODD, JOHN DODD, JOHN DODD, JOHN DOMEK, DAVID DOMSK, DAVID DOUST, MATTHEW DRUG STUDIES AMERICA DUBBERKE, ERIK DUBFY, JOHN DUFFY, JOHN DUKE HIBROMYALGIA DUKE UNIVERSITY DUKE UNIVERSITY DUKE UNIVERSITY	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in (QuANTUM-R): An Open-label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Novel Drug against Clostridium difficile Infection Study of Tivantinib in Subjects With Inoperable An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Addressing Real-world Anticoagulant Management Issues Clinical Trial to Improve Treatment With Blood Thinners in EVOLVE-AF PCI Implementation of demOnstration pRoject for Health PLX108-10 DU176b-D-0311	CHUCK DIAZ DIBUONO DIBUONO DIBUONO DIGUVANNA DIPERSIO BOX BOX BOX BOX BOX GONZALEZ DODD DODD DODD DODD DOMEK DOMEK DOMEK DOMEK DUFFY PATKAR PATKAR PATKAR PATKAR PATKAR GRANGER ROE GRANGER RIEDEL METJIAN	LEONARD JORGE MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JANE JANE JAN	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON JACKSON JACKSON OKLAHOMA CITY OKLAHOMA CITY OKLAHOMA CITY PHOENIX MARIETTA TUSTIN CARY CARY CARY DURHAM DURHAM DURHAM DURHAM DURHAM DURHAM	CA CA CA FL NY NY MO NC NC NC NC OK FL MS MS OK OK CA CA CA CA CA CA CA CA CA NC CA NC NC NC NC NC NC NC NC NC NC NC NC NC	\$75,172,50 \$5,000,0 \$22,738,43 \$12,033,54 \$9,229,87 \$38,467,79 \$36,223,20 \$7,793,10 \$9,421,10 \$37,563,23 \$12,454,65 \$929,00 \$22,515,64 \$27,474,12 \$73,066,41 \$6,588,00 \$10,152,00 \$30,606,40 \$42,500,00 \$38,230,50 \$44,584,588 \$4,250,00 \$189,621,45 \$9,500,00 \$189,551,00 \$27,88,551,00 \$27,800,000 \$21,05,322,45 \$40,000,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$19,664,00 \$22,05,322,45 \$40,000,000 \$19,664,00 \$19
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGIOVANNA, MICHAEL DIGROVANNA, MICHAEL DIPERSIO, JOHN DIL CLINICAL RESEARCH DIL CLINICAL RESEARCH DO, DIANA DOCTORS RESEARCH MILL CONTRACT C	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- Study of DS-7080a for the Treatment of Neovascular Age- Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Addressing Real-world Anticoagulant Management Issues Clinical Trial to Improve Treatment With Blood Thinners in EVOLVE-AF PCI ImplemeNtation of GemOnstration pRoject for Health PLX108-10 DU176b-D-U311 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DI GIOVANNA DIFERSIO BOX BOX BOX GONZALEZ DODD DODD DODD DOMEK DOUST TARK DUFFY PATKAR PATKAR PATKAR PATKAR HERNANDEZ GRANGER RIEDEL METJIAN DUNN DUNN	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JOHN DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID DAVID CHN DAVIN ASHWIN ASHWIN ASHWIN ASHWIN ASHWIN CHRISTOPHER MATTHEW CHRISTOPHER RICHARD ARA MICHAEL	ALAMO HIALEAH HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON JACKSON OKLAHOMA CITY PHOENIX MARIETTA TUSTIN CARY CARY DURHAM DURHAM DURHAM DURHAM DURHAM DURHAM DURHAM	CA CA CA CA CA CA CA CA CA CA CA CA CA C	\$75,172,50 \$5,000,0 \$22,738,43 \$12,033,54 \$9,229,87 \$38,467,79 \$36,223,20 \$7,793,10 \$9,421,10 \$37,563,23 \$12,454,65 \$929,00 \$22,515,64 \$27,474,12 \$73,066,41 \$6,588,00 \$10,152,00 \$30,690,69 \$26,93 \$64,584,58 \$4,250,00 \$33,954,54 \$788,551,00 \$27,80,00,00 \$27,105,21,05 \$9,500,00 \$23,354,54 \$788,551,00 \$27,80,00,00 \$22,105,322,45 \$40,000,00 \$19,664,00 \$379,664,00 \$24,059,65 \$10,6821,41 \$75,965 \$24,059,65 \$25,050,6
DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIBUONO, MARK DIGOVANNA, MICHAEL DIPERSIO, JOHN DIJ, CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DJL CLINICAL RESEARCH DODD, JOHN DODD, JOHN DODD, JOHN DOMEK, DAVID DOMEK, DAVID DOMEK, DAVID DUBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBBERKE, ERIK DUBFY, JOHN DUFFY, STTY DUKE UNIVERSITY	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in (QuANTUM-R): An Open-Label Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of DS-7080a for the Treatment of Neovascular Age- Study of DS-7080a for the Treatment of Neovascular Age- Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Addressing Real-world Anticoagulant Management Issues Clinical Trial to Improve Treatment With Blood Thinners in EVOLVE-AF PCI ImplemeNtation of GemOnstration pRoject for Health PLX108-10 DU176b-D-U311 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	CHUCK DIAZ DIBUONO DIBUONO DIBUONO DIGUVANNA DIPERSIO BOX BOX BOX BOX BOX BOX DODD DODD DODD	LEONARD JORGE MARK MARK MARK MICHAEL JOHN JANE JANE JANE JANE JANE JANE JOHN DAVID DAVID DAVID DAVID DAVID DAVID DAVID JOHN MATTHEW MARVIN ASHWIN ASHWIN ADRIAN CHRISTOPHER MATTHEW CHRISTOPHER RICHARD ARA MICHAEL	ALAMO HIALEAH STATEN ISLAND STATEN ISLAND NORTH MASSAPEQUA SAINT LOUIS CHARLOTTE CHARLOTTE CHARLOTTE CHARLOTTE CORAL GABLES JACKSON OKLAHOMA CITY PHOENIX MARIETTA TUSTIN CARY CUSTIN CARY DURHAM DURHAM DURHAM DURHAM DURHAM DURHAM DURHAM DURHAM	CA CA CA FL NY NY MO NC NC NC NC OK FL MS MS OK OK CA CA CA CA CA CA CA CA CA NC CA NC NC NC NC NC NC NC NC NC NC NC NC NC	\$75,172,50 \$5,000.0 \$22,738.43 \$12,033,54 \$9,229.87 \$38,467.79 \$36,223,20 \$7,793,10 \$9,421.10 \$37,563,23 \$12,454.65 \$9290.0 \$22,515.64 \$27,474.12 \$73,066.458.00 \$10,152.00 \$60,204.60 \$38,230,50 \$33,690.69 \$38,230,50 \$33,690.69 \$38,230,50 \$33,690.69 \$33,690.69 \$33,690.69 \$33,691.45 \$9,500.0 \$33,3954.54 \$788,551.00 \$27,800.00 \$21,05,322.45 \$40,000.00 \$319,664.00 \$57,90 \$24,059.65

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
EGELHOF, RICHARD	An Open-Label Extension Study of DS-5565 for 52 Weeks in				Researcher	\$12,320.10
EGELHOF, RICHARD	Treatment of Pain Associated With Fibromyalgia	EGELHOF	RICHARD	WICHITA	KS	\$85,579.02
ELECTROPHYSIOLOGY RESEARCH	A Phase 4, Randomized, Open Label, Multicenter,	SAKSENA	SANJEEV	WARREN	NJ	\$227,372.90
ELIAS RESEARCH ASSOCIATION LLC		GARCIA	FRANCISCO	SACRAMENTO	CA	\$4,000.00
ELIAS RESEARCH ASSOCIATION LLC	+	GARRISON	JAMES	SAN ANTONIO BILOXI	TX MS	\$4,000.00
ELIAS RESEARCH ASSOCIATION LLC ELIAS RESEARCH ASSOCIATION LLC	+	GORGI-MIKHAIL HOEKSTRA	MAGDY JOHN	RICHMOND	VA	\$500.00 \$4,000.00
ELIAS RESEARCH ASSOCIATION LLC		NASEERUDDIN	SYED	SAINT CLOUD	FL	\$3,345.18
ELIAS RESEARCH ASSOCIATION LLC	1	NEUTEL	JOEL	TUSTIN	CA	\$4,077.97
ELIAS RESEARCH ASSOCIATION LLC	1	TOLGYESI	SONIA	MIAMI	FL	\$4,000.00
ELIAS RESEARCH ASSOCIATION LLC		VALOR	ELENA	MIAMI	FL	\$4,000.00
ELITE CLINICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia	TORRES CONSUEGRA	AURELIO	HIALEAH	FL	\$126,163.41
ELLIPSIS RESEARCH GROUP LLC		SERJE	JORGE	BROOKLYN	NY	\$3,000.00
EMANUEL SHAOULIAN M D CARDIOLOGY AND RES	Edoxaban vs. Warfarin in Subjects Undergoing	SHAOULIAN	EMANUEL	NEWPORT BEACH	CA	\$2,920.68
EMORY CHILDREN'S CENTER	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	MUIR	ANDREW	AUGUSTA	GA	\$9,445.45
EMORY UNIVERSITY	DU176b-D-U311	GADDH	MANILA	ATLANTA	GA	\$15.40
EMORY UNIVERSITY	Study to Evaluate the Efficacy, Safety, and	BOULIS	NICHOLAS	CLEVELAND	OH	\$1,315.18
ENCOMPASS CLINCIAL RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	LIPETZ	ROBERT	SPRING VALLEY	CA	\$76,061.16
ENSZ, DAVID	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ENC7	DAVID	OMAHA	NE	\$2,750.00 \$29,205.24
ENSZ, DAVID ERBA, HARRY	Treatment of Pain Associated With Fibromyalgia Quizartinib With Standard of Care Chemotherapy and as	ENSZ	DAVID	OMAHA	NE	\$29,205.24 \$11,735.09
ERMAN, MILTON	Treatment of Pain Associated With Fibromyalgia	ERMAN	MILTON	SAN DIEGO	CA	\$13,445.10
ERVIN, JOHN	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ERVIN	JOHN	KANSAS CITY	мо	\$14,328.36
ERVIN, JOHN	Treatment of Pain Associated With Fibromyalgia	ERVIN	JOHN	KANSAS CITY	MO	\$63,815.23
ESSINK, BEAL	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ESSINK	BEAL	SALEM	OR	\$17,771.25
ESSINK, BEAL	Treatment of Pain Associated With Fibromyalgia	ESSINK	BEAL	SALEM	OR	\$124,587.00
ESSINK, BRANDON	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ESSINK	BRANDON	CREIGHTON	NE	\$8,125.65
ESSINK, BRANDON	Treatment of Pain Associated With Fibromyalgia	ESSINK	BRANDON	CREIGHTON	NE	\$39,288.47
EXEMPLAR RESEARCH INC.		PAINE	WARD	MORGANTOWN	WV	\$7,172.50
EZEKOWITZ, MICHAEL	A Prospective, Randomized, Open-Label Blinded Endpont				ļ]	\$10,207.91
EZEKOWITZ, MICHAEL	A Prospective, Randomized, Open-Label Blinded Endpont					\$66.67
EZEKOWITZ, MICHAEL	Edoxaban vs. Warfarin in Subjects Undergoing					\$62.80
EZEKOWITZ, MICHAEL	PLX3397 Phase 3 Study for Pigmented Villonodular		CTEFAN	LIACKENGACK	NU I	\$2,232.50
FADERL, STEFAN FEAVER, BRIAN	(QuANTUM-R): An Open-label Study of Quizartinib Treatment of Pain Associated With Fibromyalgia	FADERL FEAVER	STEFAN BRIAN	HACKENSACK LAKE JACKSON	NJ TX	\$4,329.00 \$1,942.32
FEAVER, BRIAN FELDMAN, NEIL	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	FEAVER	BRIAN	LAKE JACKSON	IX	\$1,942.32
FIDELHOLTZ, JAMES	An Open-Label Extension Study of DS-5565 for 52 Weeks in		JAMES	CINCINNATI	ОН	\$8,791.83
FIDELHOLTZ, JAMES	Safety Study of DS-5565 for Treatment of Fibromyalgia	FIDELHOLTZ	JAMES	CINCINNATI	он	\$5,000.00
FIDELHOLTZ, JAMES	Safety Study of DS-5565 for Treatment of Fibromyalgia		5,44125		0.11	\$1,248.27
FIDELHOLTZ, JAMES	Treatment of Pain Associated With Fibromyalgia	FIDELHOLTZ	JAMES	CINCINNATI	ОН	\$43,257.04
FINK, GARY	An Open-Label Extension Study of DS-5565 for 52 Weeks in	FINK	GARY	NORTH CHARLESTON	SC	\$22,741.29
FINK, GARY	Treatment of Pain Associated With Fibromyalgia	FINK	GARY	NORTH CHARLESTON	SC	\$84,571.20
FINLAY MEDICAL RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	SALINA	JUAN	HIALEAH	FL	\$41,428.12
FINLAY MEDICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia	SALINA	JUAN	HIALEAH	FL	\$156,534.74
FINN, RICHARD	PLX3397 Phase 3 Study for Pigmented Villonodular					\$66.44
FIRST COAST CARDIOVASCULAR INSTITUTE	DU176b-E-U210	KHATIB	YAZAN	JACKSONVILLE	FL	\$2,374.00
FLITMAN, STEPHEN	An Open-Label Extension Study of DS-5565 for 52 Weeks in	FLITMAN	STEPHEN	PHOENIX	AZ	\$3,500.00
FLITMAN, STEPHEN	Treatment of Pain Associated With Fibromyalgia	FLITMAN	STEPHEN	PHOENIX	AZ	\$21,751.86
FLORETE, ORLANDO	Treatment of Pain Associated With Fibromyalgia	FLORETE CUTLER	ORLANDO	JACKSONVILLE	FL	\$4,614.14 \$4,000.00
FLORIDA CLINICAL RESEARCH CENTER LLC FLORIDA CLINICAL RESEARCH CENTER LLC	+	KANE	ANDREW MARTIN	UNIVERSITY PARK ALTAMONTE SPRINGS	FL	\$4,000.00
FORSTOT, JOSEPH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	FORSTOT	JOSEPH	BOCA RATON	FL	\$12,969.52
FORSTOT, JOSEPH	Treatment of Pain Associated With Fibromyalgia	FORSTOT	JOSEPH	BOCA RATON	FL	\$31,903.00
FOUNDERS RESEARCH CORPORATION	Treatment of Pain Associated With Fibromyalgia	YEOMAN	GARY	PHILADELPHIA	PA	\$2,832.00
FOX VALLEY RESEARCH CENTER LLC	DU176b-E-U210	GILL	SANTOSH	AURORA	IL	\$4,158.70
FRESTON, JAMES	DS-5565 Phase III Study for Diabetic Peripheral					\$2,925.45
FROEDTERT MEDICAL C WISCONSIN	DU176b-D-U311	BAUMANN KREUZIGER	LISA	MILWAUKEE	WI	\$57.90
FUTURESEARCH TRIALS OF DALLAS LP	Treatment of Pain Associated With Fibromyalgia	DOWNING	MICHAEL	DALLAS	ТΧ	\$119,441.21
FUTURESEARCH TRIALS OF DALLAS LP		DOWNING	MICHAEL	DALLAS	тх	\$5,000.00
FUTURESEARCH TRIALS OF NEUROLOGY LP	Treatment of Pain Associated With Fibromyalgia	HUDSON	JOHN	AUSTIN	ТХ	\$195,983.67
FUTURESEARCH TRIALS OF NEUROLOGY LP	<u></u>	HUDSON	JOHN	AUSTIN	ТХ	\$10,000.00
GABRAIL CANCER CENTER RESEARCH LLC	TIVANTINIB	GABRAIL	NASHAT	CANTON	OH	\$6,179.58
GANGULY, SIDDHARTHA	(QuANTUM-R): An Open-label Study of Quizartinib	GANGULY	SIDDHARTHA	WESTWOOD	KS	\$36,601.99
GARCIA, FRANCISCO GEFFNER, MITCHELL	Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study	GARCIA	FRANCISCO	SACRAMENTO	CA	\$44,362.14 \$4,551.77
GENOVESE, MARK	DS2626 Compound A			1		\$4,551.77 \$111.41
GEODYSSEY RESEARCH LLC	DS2020 Compound A	JOHNSON	THOMAS	VERO BEACH	FL	\$4,250.00
GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE	Study of Tivantinib in Subjects With Inoperable	HE	AIWU	WASHINGTON	DC	\$67.30
GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE	TC00001950	HE	AIWU	WASHINGTON	DC	\$232.28
GEORGIA INSTITUTE FOR CLINICAL RESEARCH LLC	Treatment of Pain Associated With Fibromyalgia	GRASSO	ANTHONY	MARIETTA	GA	\$15,141.15
GITT, JEFFREY	Treatment of Pain Associated With Fibromyalgia	GITT	JEFFREY	PHOENIX	AZ	\$9,207.00
GITT, JEFFREY	Treatment of Pain Associated With Fibromyalgia					\$4,000.00
				1	ļ]	\$132.27
GIUGLIANO, ROBERT	Global Study to Assess the Safety and Effectiveness of					\$41,073.74
GLICK, IRA	Treatment of Pain Associated With Fibromyalgia	GLICK	IRA	STANFORD	CA	
GLICK, IRA GLOBAL RESEARCH MANAGEMENT	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	LA	DAN	GLENDALE	CA	\$12,381.18
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia					\$12,381.18 \$54,832.48
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of	LA GOENJIAN	DAN ARMEN	GLENDALE LONG BEACH	CA CA	\$12,381.18 \$54,832.48 \$920.00
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in	LA GOENJIAN SAINI	DAN ARMEN HARVINDAR	GLENDALE LONG BEACH ORLANDO	CA CA FL	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	LA GOENJIAN	DAN ARMEN	GLENDALE LONG BEACH	CA CA	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTE, WILLIAM	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	LA GOENJIAN SAINI GONTE	DAN ARMEN HARVINDAR WILLIAM	GLENDALE LONG BEACH ORLANDO SOUTHFIELD	CA CA FL	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	LA GOENJIAN SAINI	DAN ARMEN HARVINDAR	GLENDALE LONG BEACH ORLANDO	CA CA FL MI	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTE, WILLIAM GONZALEZ, MISAEL	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	LA GOENJIAN SAINI GONTE GONZALEZ	DAN ARMEN HARVINDAR WILLIAM MISAEL	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES	CA CA FL MI FL	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05 \$98,254.84
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTEL, WILLIAM GONZALEZ, MISAEL GONZALEZ, MISAEL	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ	DAN ARMEN HARVINDAR WILLIAM MISAEL MISAEL	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES	CA CA FL MI FL FL	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOCINIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTE, WILLIAM GONTE, WILLIAM GONZALEZ, MISAEL GORDAL, JAMES	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GORDON	DAN ARMEN HARVINDAR WILLIAM MISAEL JAMES	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON	CA CA FL MI FL FL FL AZ	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$\$3,389.05 \$98,254.84 \$15,301.89
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTZ, WILLIAM GONZALEZ, MISAEL GONZALEZ, MISAEL GORDON, JAMES GORGI-MIKHAIL, MAGDY	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Safety Study of DS-5565 for Treatment of Fibromyalgia	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GONZALEZ GORDON GORGI-MIKHAIL	DAN ARMEN HARVINDAR WILLIAM MISAEL JAMES MAGDY	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI	CA CA FL MI FL FL FL AZ MS	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05 \$98,254.84 \$15,301.89 \$4,000.00
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONZALEZ, MISAEL GONZALEZ, MISAEL GONZALEZ, MISAEL GORGI-MIKHALI, MAGDY GORGI-MIKHAL, MAGDY	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GORDON GORGI-MIKHAIL GORGI-MIKHAIL	DAN ARMEN HARVINDAR WILLIAM MISAEL JAMES MAGDY	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI	CA CA FL MI FL FL FL AZ MS	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05 \$98,254.84 \$15,301.89 \$4,000.00 \$138,745.06
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTZ, WILLIAM GONZALEZ, MISAEL GONZALEZ, MISAEL GORZHON, JAMES GORGI-MIKHAIL, MAGDY GORGI-MIKHAIL, MAGDY GORGI-MIKHAIL, MAGDY GOTTSCHLLCH, GREGORY GOUNDER, MRINAL	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GORDON GORGI-MIKHAIL GORGI-MIKHAIL	DAN ARMEN HARVINDAR WILLIAM MISAEL JAMES MAGDY MAGDY	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI BILOXI	CA CA FL MI FL FL FL AZ MS MS	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05 \$98,254.84 \$15,301.89 \$4,000.00 \$138,745.06 \$6,981.55
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONZALEZ, MISAEL GONZALEZ, MISAEL GORDON, JAMES GORGI-MIKHAIL, MAGDY GORGI-MIKHAIL, MAGDY GOTSCHLAL, MICHAEL GOTTSCHALK, MICHAEL GOTSCHLCH, GREGORY	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study An Open-Label Extension Study of DS-5565 for 52 Weeks in	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GORDON GORGI-MIKHAIL GORGI-MIKHAIL	DAN ARMEN HARVINDAR WILLIAM MISAEL JAMES MAGDY MAGDY	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI BILOXI	CA CA FL MI FL FL FL AZ MS MS	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05 \$98,254.84 \$15,301.89 \$4,000.00 \$138,745.06 \$6,981.55 \$153,475.84
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONZALEZ, MISAEL GONZALEZ, MISAEL GORZALEZ, MISAEL GORGI-MIKHAIL, MAGDY GORGI-MIKHAIL, MAGDY GORGI-MIKHAIL, MAGDY GORGI-MIKHAIL, MAGDY GOTTSCHALK, MICHAEL GOTTSCHALK, MICHAEL GOUNDER, MRINAL	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study An Open-Label Extension Study of DS-5565 for 52 Weeks in	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GORDON GORGI-MIKHAIL GORGI-MIKHAIL	DAN ARMEN HARVINDAR WILLIAM MISAEL JAMES MAGDY MAGDY	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI BILOXI	CA CA FL MI FL FL FL AZ MS MS	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05 \$98,254.84 \$15,301.99 \$4,000.00 \$138,745.06 \$6,981.55 \$153,475.84 \$7,258.83
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENJIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTZ, WILLIAM GONZALEZ, MISAEL GONZALEZ, MISAEL GORDAN, JAMES GORGI-MIKHAL, MAGDY GORGI-MIKHAL, MAGDY GOTTSCHLICH, GREGORY GUUNDER, MRINAL GOUNDER, MRINAL GRANT, DAVID GRAPT LAKES CLINICAL TRIALS LLC	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Safety Study of DS-5565 for Treatment of Fibromyalgia Safety Study of DS-5565 for Treatment of Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study An Open-Label Extension Study of DS-5565 for 52 Weeks in Study to Evaluate the Safety, Tolerability and Treatment of Pain Associated With Fibromyalgia	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GORZON GONGI-MIKHAIL GORGI-MIKHAIL GOTTSCHLICH GRANT ROSS	DAN ARMEN HARVINDAR WILLIAM MISAEL JAMES MAGDY MAGDY GREGORY DAVID JEFFREY	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI BILOXI GINCINNATI CINCINNATI	CA CA FL FL FL FL AZ MS MS OH OH TX IL	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05 \$98,254.84 \$15,301.89 \$4,000.00 \$138,745.06 \$6,981.55 \$153,475.84 \$7,258.83 \$16.67 \$35,522.83 \$4,000.00
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTE, WILLIAM GONTE, WILLIAM GONZALEZ, MISAEL GORDON, JAMES GORGI-MIKHAL, MAGDY GORGI-MIKHAL, MAGDY GORGI-MIKHAL, MAGDY GOTTSCHALK, MICHAEL GOTTSCHLCH, GREGORY GOUNDER, MRINAL GONNAL GONNAL GRANT, DAVID GREAT LAKES CLINICAL TRIALS LLC GREAT LAKES MEDICAL RESEARCH LLC	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Safety Study of DS-S565 for Treatment of Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study An Open-Label Extension Study of DS-S565 for 52 Weeks in Study to Evaluate the Safety, Tolerability and Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study An Open-Label Extension Study of DS-S565 for 52 Weeks in Study to Evaluate the Safety, Tolerability and Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GORZON GONGI-MIKHAIL GORGI-MIKHAIL GOTTSCHLICH GRANT ROSS	DAN ARMEN HARVINDAR WILLIAM MISAEL MISAEL JAMES MAGDY GREGORY DAVID	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI BILOXI CINCINNATI CINCINNATI	CA CA FL MI FL FL FL AZ MS MS OH	\$12,381.18 \$54,832.48 \$920.00 \$338,101.70 \$5,555.92 \$4,500.00 \$138,745.06 \$6,981.55 \$153,475.84 \$7,258.83 \$16.67 \$5,522.83 \$4,000.00 \$4,55,522.83
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONZALEZ, MISAEL GONZALEZ, MISAEL GORDON, JAMES GORGI-MIKHAIL, MAGDY GORGI-MIKHAIL, MAGDY GOTSCHALK, MICHAEL GOTTSCHALK, MICHAEL GOTTSCHALK, MICHAEL GOTTSCHALK, MICHAEL GONDER, MRINAL GRANT, DAVID GRAFT LAKES CLINICAL TRIALS LLC GREEND, EWARD	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Study to Evaluate the Safety, Tolerability and Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Study of Tivantinib in Subjects With Inoperable	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GONZALEZ GORD-NI GORGI-MIKHAIL GORGI-MIKHAIL GOTSCHLICH GRANT ROSS BOYLAN	DAN ARMEN HARVINDAR WILLIAM MISAEL MISAEL JAMES MAGDY MAGDY GREGORY GREGORY DAVID JEFFREY PATRICK	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI BILOXI BILOXI CINCINNATI CINCINNATI SAN ANTONIO NORTHBROOK MENTOR	CA CA CA FL FL FL FL FL FL FL FL FL OH OH CH OH OH OH	\$12,381.18 \$54,832.48 \$920.00 \$358,101.70 \$5,555.92 \$4,500.00 \$53,389.05 \$98,254.44 \$15,301.89 \$4,000.00 \$138,745.06 \$6,981.55 \$153,475.84 \$7,258.83 \$16.67 \$35,522.83 \$4,000.00 \$4,500.00 \$4,500.00 \$1,205.79
GLICK, IRA GLOBAL RESEARCH MANAGEMENT GOENIAN, ARMEN GOLDHABER, SAMUEL GOLDPOINT CLINICAL RESEARCH LLC GONTE, WILLIAM GONTE, WILLIAM GONZALEZ, MISAEL GORDON, JAMES GORGI-MIKHALI, MAGDY GORTSCHALK, MICHAEL GOTTSCHALK, MICHAEL GOTTSCHALK, MICHAEL GOUNDER, MRINAL GOUNDER, MRINAL GONDAE, MRINAL GRANT, DAVID GREAT LAKES CLINICAL TRIALS LLC GREAT LAKES MEDICAL RESEARCH LLC	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Safety Study of DS-S565 for Treatment of Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study An Open-Label Extension Study of DS-S565 for 52 Weeks in Study to Evaluate the Safety, Tolerability and Treatment of Pain Associated With Fibromyalgia Colesevelam Pediatric Type 2 Diabetes Mellitus Study An Open-Label Extension Study of DS-S565 for 52 Weeks in Study to Evaluate the Safety, Tolerability and Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in	LA GOENJIAN SAINI GONTE GONZALEZ GONZALEZ GORZON GONGI-MIKHAIL GORGI-MIKHAIL GOTTSCHLICH GRANT ROSS	DAN ARMEN HARVINDAR WILLIAM MISAEL JAMES MAGDY MAGDY GREGORY DAVID JEFFREY	GLENDALE LONG BEACH ORLANDO SOUTHFIELD CORAL GABLES CORAL GABLES TUCSON BILOXI BILOXI GINCINNATI CINCINNATI	CA CA FL FL FL FL AZ MS MS OH OH TX IL	\$12,381.18 \$54,832.48 \$920.00 \$338,101.70 \$5,555.92 \$4,500.00 \$138,745.06 \$6,981.55 \$153,475.84 \$7,258.83 \$16.67 \$5,522.83 \$4,000.00 \$4,55,522.83

Payee	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Total
GROSS, PAUL	An Open-Label Extension Study of DS-5565 for 52 Weeks in	Last Name GROSS	First Name PAUL	ALLENTOWN	Researcher PA	\$14,456.26
GROSS, PAUL	Treatment of Pain Associated With Fibromyalgia	GROSS	PAUL	ALLENTOWN	PA	\$81,978.74
GROSZ, DANIEL		GROSZ	DANIEL	ENCINO	CA	\$12,479.40
GROSZ, DANIEL	Treatment of Pain Associated With Fibromyalgia	GROSZ	DANIEL	ENCINO	CA	\$92,350.80
GURBEL, PAUL GUTIERREZ STONE, JESUS	Influence of Edoxaban on Coagulability and Thrombin An Open-Label Extension Study of DS-5565 for 52 Weeks in	GURBEL GUTIERREZ STONE	PAUL JESUS	BALTIMORE ORLANDO	MD FL	\$86,040.00 \$4,000.00
GUTIERREZ STONE, JESUS	Treatment of Pain Associated With Fibromyalgia	GUTIERREZ STONE	JESUS	ORLANDO	FL	\$102,611.95
H LEE MOFFITT CANCER CENTER AND	PLX108-10	REED	DAMON	TAMPA	FL	\$16,428.70
HAAK, LOGAN	Study of DS-7080a for the Treatment of Neovascular Age-					\$5,610.66
HACKENSACK UNIVERSITY MEDICAL CENTER	ARQ197-A-U160	GUTIERREZ	MARTIN	HACKENSACK	NJ	\$46,544.20
HACKENSACK UNIVERSITY MEDICAL CENTER HACKENSACK UNIVERSITY MEDICAL CENTER	Pharmacokinetics of Tivantinib in Subjects With Advanced Study of Tivantinib in Subjects With Inoperable	GUTIERREZ GUTIERREZ	MARTIN	HACKENSACK HACKENSACK	NJ NJ	\$25,377.31 \$3,573.45
HAGGAG, AMINA	Treatment of Pain Associated With Fibromyalgia	HAGGAG	AMINA	NORTHRIDGE	CA	\$3,573.45 \$13,336.22
HARPER, LINDA		HARPER	LINDA	ORLANDO	FL	\$70,717.56
HARPER, LINDA	Treatment of Pain Associated With Fibromyalgia	HARPER	LINDA	ORLANDO	FL	\$227,360.68
HARPER, WAYNE		HARPER	WAYNE	RALEIGH	NC	\$5,733.00
HARPER, WAYNE	Treatment of Pain Associated With Fibromyalgia	HARPER	WAYNE	RALEIGH	NC	\$92,285.25
HARRIS, WILLIAM HASBRO CHILDREN'S HOSPITAL	Study of Tivantinib in Subjects With Inoperable Phase 1 Pediatric PKPD Study	CHAWLA	ANJULIKA	PROVIDENCE	RI	\$1,818.78 \$7,050.00
HASSMAN, DAVID	An Open-Label Extension Study of DS-5565 for 52 Weeks in	HASSMAN	DAVID	BERLIN	NJ	\$7,247.37
HASSMAN, DAVID	Treatment of Pain Associated With Fibromyalgia	HASSMAN	DAVID	BERLIN	NJ	\$29,509.24
HAYMOND, MOREY	Colesevelam Pediatric Type 2 Diabetes Mellitus Study					\$1,364.64
HE, AIWU	PLX3397 Phase 3 Study for Pigmented Villonodular					\$66.44
HE, AIWU	Study of Tivantinib in Subjects With Inoperable		-	-		\$1,235.59
HEALEY, JOHN HEALTH POINT MEDICAL GROUP INC.	Neoadjuvant and Personalized Adaptive Novel Agents to An Open-Label Extension Study of DS-5565 for 52 Weeks in		JOEL	ТАМРА	FL	\$7,116.38 \$3,500.00
HEALTH POINT MEDICAL GROUP INC. HEALTH POINT MEDICAL GROUP INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	SILVERFIELD	JOEL	ТАМРА	FL	\$3,500.00 \$44,601.88
HEALTH FORT MEDICAL GROUP		MIZUTANI	WESLEY	LONG BEACH	CA	\$5,000.00
HEARTLAND RESEARCH ASSOCIATION		EGELHOF	RICHARD	WICHITA	KS	\$3,500.00
HEARTLAND RESEARCH ASSOCIATION		HOLDEMAN	TROY	NEWTON	KS	\$10,140.00
HEARTLAND RESEARCH ASSOCIATION	Church of Theoretic is in Cubic of Maria 1	KLEIN	THOMAS	WICHITA	KS	\$12,684.50
HELP HEALTH AND SCIENCE CENTER HELP HEALTH AND SCIENCE CENTER	Study of Tivantinib in Subjects With Inoperable TC00001950	CABRERA CABRERA	RONIEL	GAINESVILLE GAINESVILLE	FL	\$551.70 \$209.08
HEM - ONCOLOGY ASSOCIATION OF THE TREASURE	Study of Patritumab in Combination With Study of	IANNOTTI	NICHOLAS	PORT ST LUCIE	FL	\$10,276.86
HOLDEMAN, TROY	, , , , , , , , , , , , , , , , , , , ,	HOLDEMAN	TROY	NEWTON	KS	\$38,096.90
HOLDEMAN, TROY	Treatment of Pain Associated With Fibromyalgia	HOLDEMAN	TROY	NEWTON	KS	\$125,837.48
HOLE, SUSAN	Treatment of Pain Associated With Fibromyalgia	HOLE	SUSAN	EDGEWATER	FL	\$15,763.43
HOMESTEAD MEDICAL RESEARCH INC.		FELDMAN	MICHAEL	VILLAGE OF PALMETTO	FL	\$10,185.94
HOMESTEAD MEDICAL RESEARCH INC. HORWITZ, ALEXANDER	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	FELDMAN HORWITZ	MICHAEL ALEXANDER	VILLAGE OF PALMETTO SALEM	FL OR	\$70,650.93 \$36,085.50
HORWITZ, ALEXANDER	Treatment of Pain Associated With Fibromyalgia	HORWITZ	ALEXANDER	SALEM	OR	\$150,151.50
HOUSTON ENDOSCOPY & RESEARCH CENTER		MEHRA	VIKRAM	HOUSTON	TX	\$5,100.00
HUFFMAN, CYNTHIA	Treatment of Pain Associated With Fibromyalgia	HUFFMAN	CYNTHIA	TAMPA	FL	\$187,055.30
HUYNH, BOBBY	Treatment of Pain Associated With Fibromyalgia	HUYNH	BOBBY	RICHARDSON	ТХ	\$9,588.17
IHAB R KAMEL	A Phase 3, Randomized, Double-Blind Study of Tivantinib	KAMEL	IHAB	BALTIMORE	MD	\$2,800.00
IHAB R KAMEL IMAGAWA, DAVID	TIVANTINIB Study of Tivantinib in Subjects With Inoperable	KAMEL	IHAB	BALTIMORE	MD	\$15,750.00 \$327.59
IMPERATO, ANNA	Treatment of Pain Associated With Fibromyalgia	IMPERATO	ANNA	MANHASSET	NY	\$14,856.72
IMPERATO, ANNA	Treatment of Pain Associated With Fibromyalgia					\$3,313.00
INDEPENDENT CLINICAL RESEARCHERS		WOLFSON	ERIC	LAS VEGAS	NV	\$5,000.00
INDIANA UNIVERSITY	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	NABHAN	ZEINA	INDIANAPOLIS	IN	\$12,984.00
	DS2248-A-U101	JALAL	SHADIA	INDIANAPOLIS	IN	\$10,483.12
INDIANA UNIVERSITY INDIANA UNIVERSITY HEALTH GOSHEN CENTER FOR	Study to Evaluate the Efficacy, Safety, and Study of Patritumab in Combination With Study of	HORN KIO	ERIC EBENEZER	INDIANAPOLIS GOSHEN	IN IN	\$29,197.53 \$9,250.00
INFINITY RESEARCH GROUP LLC	DU176b-E-U210	PASTOR CERVANTES	JUAN	HOLLYWOOD	FL	\$5,297.00
INJURY CARE MEDICAL CENTER		RADNOVICH	RICHARD	BOISE	ID	\$4,150.24
INJURY CARE MEDICAL CENTER	Treatment of Pain Associated With Fibromyalgia	RADNOVICH	RICHARD	BOISE	ID	\$51,202.16
INNOVATIVE CLINICAL TRIALS - SAN ANTONIO	An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS		SAN ANTONIO		
INNOVATIVE CLINICAL TRIALS - SAN ANTONIO			CHARLES		тх	\$3,500.00
	Treatment of Pain Associated With Fibromyalgia	ANDREWS	CHARLES	SAN ANTONIO	ТХ	\$31,920.07
INSTITUTE FOR CLINICAL RESEARCH - HOLY NAME	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210	ANDREWS RUNDBACK	CHARLES JOHN	SAN ANTONIO TEANECK	TX NJ	\$31,920.07 \$43,187.30
INSTITUTE FOR CLINICAL RESEARCH - HOLY NAME INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE	Treatment of Pain Associated With Fibromyalgia	ANDREWS RUNDBACK INTELISANO	CHARLES	SAN ANTONIO	ТХ	\$31,920.07
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU	CHARLES JOHN RONDALD SRINIVAS SRINIVAS	SAN ANTONIO TEANECK BLACKWOOD	TX NJ NJ KS KS	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND	TX NJ KS KS OK	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPOND LLC	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH	TX NJ NJ KS KS OK FL	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPOND LLC INTERSPOND LLC	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS	TX NJ NJ KS KS OK FL MT	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPO	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN HORN	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO	TX NJ NJ KS OK FL MT TX	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$5,000.00
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPOND LLC INTERSPOND LLC	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS	TX NJ NJ KS KS OK FL MT	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHRISTOPHER CHERIAN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK	TX NJ NJ NJ KS KS KS OK FL MT TX OK GA FL	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,200.00 \$
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPO	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE JORGE UIRTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY	TX NJ NJ KS KS OK FL MT TX OK GA FL NC	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$5,900.00 \$5,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHEIAN JONATHAN ROBERT	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD	ТХ NJ KS KS OK FL MT TX OK GA FL NC IN	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$31,140.63 \$3,900.00 \$31,892.40
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS	TX NJ NJ KS KS OK FL MT TX OK GA FL NC IN CA	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,140.63 \$13,140.63 \$3,900.00 \$31,892.40 \$31,571.60
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE JORGE UIRTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD	ТХ NJ KS KS OK FL MT TX OK GA FL NC IN	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$31,140.63 \$3,900.00 \$31,892.40
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER SCHUSTER	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS	TX NJ NJ KS KS OK FL TX OK GA FL NC NC CA CA	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$5,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,900.00 \$34,90
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER SCHUSTER JARRETT JARRETT	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE JORGE UICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN THOMAS	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS	TX NJ	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$3,900.00 \$5,900.00 \$3,900.00 \$3,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,921.40.63 \$3,328.24 \$32,299.78 \$5,000.00 \$273,185.81
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPO	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DSI040-A-U103	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER JARRETT JARRETT KIRMANI	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN THOMAS JAWAD	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS HIGH POINT HIGH POINT EDISON	ТХ NJ KS KS OK FL MT TX OK GA FL NC NC NC NC NJ	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$33,802.40 \$34,802.40 \$34,802.40 \$35,800.40 \$35,800.40 \$32,900.40
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC ITZCOVICH-SCHUSTER, JOSE IJRRETT, THOMAS JARRETT, THOMAS JARRET MENNEL JFK MD CENTER IJMIN WANG MD PA	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER JARRETT JARRETT KIRMANI WANG	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN THOMAS JAWAD JIMIN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS HIGH POINT EDISON HOUSTON	ТХ NJ NJ KS KS OK FL MT TX OK GA FL NC CA CA CA CA NC NU TX	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$33,900.00 \$33,900.00 \$31,140.63 \$3,900.00 \$33,900.00 \$31,892.40 \$13,571.60 \$63,328.24 \$32,299.78 \$5,000.00 \$2273,185.81 \$2266.64 \$4,500.00
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	ANDREWS RUNDBACK INTELISANO NALAMACHU OCONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER JARRETT JARRETT KIRMANI WANG WANG	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE JORGE UICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN THOMAS JAWAD JIMIN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS HIGH POINT EDISON HOUSTON	ТХ NJ NJ NJ NJ KS KS OK OK FL MT TX OK GA FL NC NC CA CC CA CC CA NC NJ TX TX TX TX TX NT TX TX NT	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$3,900.00 \$5,900.00 \$3,900.00 \$3,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$31,892.40 \$33,390.00 \$31,892.40 \$33,390.00 \$33,390.00 \$33,390.00 \$33,390.00 \$33,390.00 \$27,31,85.81 \$266.64 \$4,500.00 \$5,000.00
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPO	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Week	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLOFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER SCHUSTER JARRETT KIRMANI WANG WANG JOHNSON	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN THOMAS JAWAD JIMIN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS	TX NJ NJ KS KS OK FL MT TX OK GA FL NC NC NC NC NC NC NI TX TX TX TX TX TX TX	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$33,82,40 \$32,299.78 \$32,299.78 \$32,60 \$26,64 \$4,500.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$22,900.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,800.00 \$22,900.00 \$22
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	ANDREWS RUNDBACK INTELISANO NALAMACHU OCONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER JARRETT JARRETT KIRMANI WANG WANG	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE UICKI JORGE CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN THOMAS JAWAD JIMIN JIMIN DAVID	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS HIGH POINT EDISON HOUSTON	ТХ NJ NJ NJ NJ KS KS OK OK FL MT TX OK GA FL NC NC CA CC CA CC CA NC NJ TX TX TX TX TX NT TX TX NT	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$3,900.00 \$5,900.00 \$3,900.00 \$3,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$31,892.40 \$33,390.00 \$31,892.40 \$33,390.00 \$33,390.00 \$33,390.00 \$33,390.00 \$33,390.00 \$27,31,85.81 \$266.64 \$4,500.00 \$5,000.00
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Op	ANDREWS ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ DIAZ HAGAN HORN NAEL OLOFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER JARRETT KIRMANI WANG JOHNSON JOHNSON JOHNSON	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE UICKI JORGE CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN THOMAS JAWAD JIMIN DAVID DAVID THOMAS THOMAS	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS HIGH POINT EDISON HOUSTON HOUSTON OWENSBORO OWENSBORO OWENSBORO VERO BEACH	TX NJ NJ KS OK FL MT TX OK GA FL NC IN CA CA NC NI TX TX TX KY	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$22,040.63 \$3,900.00 \$22,040.63 \$3,900.00 \$23,900.00 \$24,500.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,200.00 \$5,000.00 \$5,200.00 \$5,000.00 \$5,200.00 \$5,000.00 \$5,200.00 \$5,200.00 \$5,000.00 \$5,200.00 \$5,000.00 \$5,200.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPONT HOMAS IDINTSON, THOMAS IDINTSON, THOMAS IDINTERSPONT HOMAS IDINTERSPOND LLC INTERSPONT HOMAS IDINTERSP	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of PA:S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of PA:S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of PA:S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain As	ANDREWS ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER JARRETT JARRETT JARRETT JARRETT KIRMANI WANG UANG JOHNSON JOHNSON JOHNSON	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN THOMAS THOMAS JIMIN JIMIN JIMIN DAVID DAVID THOMAS THOMAS THOMAS	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS HIGH POINT EDISON HOUSTON HOUSTON HOUSTON OWENSBORO OWENSBORO VERO BEACH YERO BEACH	ТХ NJ KS KS OK FL MT TX CA CA CA CA CA CA CA NC NI TX TX KY KY FL IL IL	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$33,802.40 \$34,802.40 \$35,900.00 \$22,145,815 \$266.64 \$4,500.00 \$28,508.19 \$242,126.81 \$5,400.00 \$18,298.38 \$22,273,155 \$38,900.00 \$348,293,805 \$35,400.00 \$35,293.88 \$32,293.88 \$32,293.88 \$32,293.80 \$32,400.80 \$34,293.88 \$32,293.88 \$32,293.80 \$32,200.80 \$34,200.80
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPO	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of OLS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of OLS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER JARRETT JARRETA JOHNSON JOHNSON JOHNSON	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN THOMAS THOMAS JAWAD JIMIN JIMIN JIMIN JIMIN JIMIN DAVID DAVID THOMAS THOMAS THOMAS KULUMANI BRIAN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS OWNTE HIGH POINT EDISON HOUSTON HOUSTON HOUSTON OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO	ТХ NJ KS KS KS OK FL MT TX OK GA FL NC NC NC NC NC NC NL TX TX TX KY FL FL FL FL FL CA	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$273,185.81 \$266.64 \$4,500.00 \$5,000.00 \$28,508.19 \$123,126.81 \$5,400.00 \$18,298.38 \$2,373.05 \$45,893.83
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU17bb-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of Erlotinib With or Without Investigational Drug (U3 (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLOFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER JARRETT JARRETT KIRMANI WANG UHNSON JOHNSON JOHNSON JOHNSON JOHNSON JOHNSON	CHARLES JOHN RONDALD SRINIVAS SRINIVAS SRINIVAS VICKI JORGE UICKI CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN THOMAS JAWAD JIMIN JIMIN DAVID DAVID DAVID THOMAS THOMAS THOMAS THOMAS STAMAS THOMAS	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS OWENSTON OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO	TX NJ NJ KS GK FL TX OK FL NC NC NC NC NC NC NC NC NC NL TX TX KY FL	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$22,97.85 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,200.00 \$5,200.00 \$5,000.00 \$5,237.05 \$4,583.83 \$1,1206.26 \$4,500.00 \$4,1206.26 \$4,1206.26 \$4,1206.26 \$4,1206.26 \$4,1206.26 \$4,1206.26 \$4,1206.26
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPONT HOMAS IDIOHNSON HOMAS IDIOH	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of OLS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of OLS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An	ANDREWS RUNDBACK INTELISANO NALAMACHU NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER JARRETT JARRETT JARRETT JARRETT JARRETT JARRETT JARRETT JARRETT JARRETT JOHNSON JOHNSON JOHNSON JOHNSON JOHNSON JOHNSON JONAS JONAS JONES JONES JONES	CHARLES JOHN RONDALD SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN THOMAS JIMIN JIMIN JIMIN JIMIN JIMIN DAVID DAVID DAVID THOMAS THOMAS THOMAS THOMAS KULUMANI BRIAN KATHLEEN KATHLEEN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS HIGH POINT EDISON HOUSTON OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO VERO BEACH YERO BEACH YERO REACH JOLIET SACRAMENTO WEST DES MOINES	ТХ NJ KS KS KS OK FL MT TX OK GA FL NC NC NC NC NC NC NL TX TX TX KY FL FL FL FL FL CA	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,140.63 \$33,140.63 \$33,900.00 \$31,892.40 \$31,871.60 \$63,328.24 \$32,299.78 \$5,000.00 \$273,185.81 \$266.64 \$4,500.00 \$28,500.90 \$22,73,125.81 \$266.64 \$4,500.00 \$5,000.00 \$28,500.819 \$123,126.81 \$5,400.00 \$34,8298.38 \$2,373.05 \$45,893.83 \$11,206.55 \$45,893.83 \$11,206.55 \$11,016 \$55,011.60 \$25,011.60 \$25,011.60 \$25,011.60 \$25,011.60 \$34,902.85 \$34,802.85 \$34,802.85 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$35,000.00 \$32,204.63 \$33,273.05 \$34,893.83 \$31,201.60 \$35,000.00 \$35,000.00 \$35,000.00 \$33,273.05 \$34,893.83 \$35,101.60 \$35,000.0
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU17bb-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of Erlotinib With or Without Investigational Drug (U3 (QuANTUM-R): An Open-Label Study of Quizartinib An Open-Label Extension Study of DS-5565 for 52 Weeks in	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLOFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER JARRETT JARRETT KIRMANI WANG UHNSON JOHNSON JOHNSON JOHNSON JOHNSON JOHNSON	CHARLES JOHN RONDALD SRINIVAS SRINIVAS SRINIVAS VICKI JORGE UICKI CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN THOMAS JAWAD JIMIN JIMIN DAVID DAVID DAVID THOMAS THOMAS THOMAS THOMAS STAMAS THOMAS	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS OWENSTON OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO OWENSBORO	ТХ NJ KS KS OK FL MT TX OK GA FL OK GA FL NC NC NC NC NC NC NC NC NC NC	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$22,97.85 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,000.00 \$5,200.00 \$5,200.00 \$5,000.00 \$5,237.05 \$4,583.83 \$1,1206.26 \$4,500.00 \$4,1206.26 \$4,1206.26 \$4,1206.26 \$4,1206.26 \$4,1206.26 \$4,1206.26 \$4,1206.26
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-S565 for 52 Weeks in An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-S565 f	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER JARRETT JOHNSON JOHNSON JOHNSON JOHNSON JOHNSON JONS JONS JONS DONS DONS DONS DONS DONS DONS DELGIUDICE	CHARLES JOHN RONDALD SRINIVAS SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN THOMAS THOMAS JAWAD JIMIN JIMIN JIMIN DAVID DAVID DAVID THOMAS THOMAS THOMAS KULUMANI BRIAN KATHLEEN KATHLEEN KATHLEEN KATHLEEN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS OWENSBORO WENSBORO OWENSBORO	TX NJ NJ KS OK FL MT TX OK GA FL OK GA FL NC NC NC NC NC NK TX TX FL FL IA TX TX FL	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$22,040.63 \$13,140.63 \$33,900.00 \$31,892.40 \$31,871.60 \$63,328.24 \$32,299.78 \$5,000.00 \$273,185.81 \$266.64 \$4,500.00 \$28,508.19 \$123,126.81 \$5,400.00 \$18,298.38 \$22,373.05 \$45,893.83 \$11,206.26 \$51,011.60 \$4,000.00 \$6,715.81 \$60,103.14
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTERSPO	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Op	ANDREWS ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLOFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER JARRETT JARRETT KIRMANI WANG JOHNSON JOHNSON JOHNSON JOHNSON JOHNSON JONES JONES JONES DELGIUDICE JOSEPH	CHARLES JOHN RONDALD SRINIVAS SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN THOMAS JAWAD JIMIN JIMIN DAVID DAVID DAVID DAVID DAVID THOMAS THOMAS KULUMANI BRIAN KATHLEEN KATHLEEN JOSE JOHN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHER	TX NJ NJ KS KS OK FL MT TX OK FL MT CA CA CA CA CA CA CA TX NU TX TX TX FL FL CA IX TX TX TX	\$31,920.07 \$43,187.30 \$35,902.58 \$3,500.00 \$11,079.80 \$22,040.63 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,900.00 \$31,892.40 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$33,900.00 \$273,185.81 \$5,000.00 \$273,185.81 \$5,000.00 \$28,5083.93 \$32,373.05 \$45,893.83 \$31,206.26 \$51,011.60 \$4,000.00 \$6,715.81 \$60,103.14 \$60,103.14 \$20,575.469
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU176b-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment	ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLOFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER JARRETT JARRETT JARRETT JARRETT KIRMANI WANG JOHNSON JONES DORES DELGIUDICE JOSHI JOSHI JOSHI	CHARLES JOHN RONDALD SRINIVAS SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN MARTIN THOMAS JAWAD JIMIN JAVID DAVID DAVID DAVID DAVID DAVID THOMAS THOMAS JIMIN BAVID THOMAS JIMIN JAVID THOMAS JIMIN JAVID THOMAS THOMAS THOMAS THOMAS THOMAS JOSE JOHN NANDITA NANDITA	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS OWENSBORO O	TX NJ NJ KS KS OK FL TX OK GA FL NC IN CA INC NU TX TX FL FL IA TX TX FL FL	\$31,920.07 \$43,187.30 \$3,500.00 \$11,079.80 \$22,040.63 \$8,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$3,900.00 \$22,040.63 \$13,140.63 \$3,900.00 \$23,371.05 \$63,328.24 \$32,299.78 \$5,000.00 \$273,185.81 \$266.64 \$4,500.00 \$273,185.81 \$266.64 \$4,500.00 \$273,185.81 \$266.64 \$4,500.00 \$273,185.81 \$266.64 \$4,500.00 \$273,185.81 \$266.64 \$4,500.00 \$273,185.81 \$266.64 \$4,500.00 \$273,185.81 \$266.64 \$4,500.00 \$273,185.81 \$5,000.00 \$28,508.19 \$123,126.81 \$5,000.00 \$28,508.19 \$123,126.81 \$5,000.00 \$40,0000 \$6,715.81 \$60,103.14 \$235,754.69 \$168.37
INTELISANO, RONALD INTERNATIONAL CLINICAL RESEARCH INSTITUTE INTERSPOND LLC INTER	Treatment of Pain Associated With Fibromyalgia DU17b6-E-U210 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of Erlotinib With or Without Investigational Drug (U3 (QuANTUM-R): An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Study of Erlotinib With or Without Investigational Drug (U3 (QuANTUM-R): An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment	ANDREWS ANDREWS RUNDBACK INTELISANO NALAMACHU CONRAD DIAZ HAGAN HORN NAEL OLDFIELD SAJAN WILSON HELM SCHUSTER SCHUSTER JARRETT KIRMANI WANG UJOHNSON JOHNSON JOHNN J	CHARLES JOHN RONDALD SRINIVAS SRINIVAS SRINIVAS VICKI JORGE MICHAEL CURTIS SIAVASH CHRISTOPHER CHERIAN JONATHAN ROBERT MARTIN THOMAS THOMAS JAWAD JIMIN JIMIN JIMIN DAVID DAVID DAVID THOMAS THOMAS THOMAS KULUMANI BRIAN KATHLEEN KATHLEEN KATHLEEN KATHLEEN	SAN ANTONIO TEANECK BLACKWOOD OVERLAND PARK EDMOND HIALEAH BILLINGS SAN ANTONIO OKLAHOMA CITY SAVANNAH WINTER PARK HICKORY ELWOOD SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS SHERMAN OAKS HIGH POINT EDISON HOUSTON OWENSBORO OWENSBOR	TX NJ NJ KS OK FL MT TX OK GA FL OK GA FL NC NC NC NC NC NK TX TX FL FL IA TX TX FL	\$31,920.0 \$43,187.3 \$35,902.5 \$3,500.0 \$11,079.8 \$22,040.6 \$8,900.0 \$3,892.4 \$3,892.4 \$3,892.4 \$3,892.4 \$3,892.4 \$3,892.4 \$3,892.4 \$3,920.0 \$4,893.8 \$1,1206.2 \$5,011.0 \$4,600.0 \$5,010.0 \$4,600.0 \$5,010.0 \$4,600.0 \$5,010.0 \$4,600.0 \$5,010.0 \$4,600.0 \$5,010.0 \$5,010.0 \$4,600.0 \$5,010.0 \$5,000.0 \$5,000.0 \$5,000.0 \$5,000.0 \$5,000.0 \$5,000.0

Рауее	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Total
KANE, MARTIN	Treatment of Pain Associated With Fibromyalgia	Last Name KANE	First Name MARTIN	ALTAMONTE SPRINGS	Researcher FL	\$36,048.37
KAPIL, SANJIV	Safety Study of DS-5565 for Treatment of Fibromyalgia	KAPIL	SANJIV	LAKE MARY	FL	\$6,000.00
KAPLAN, ROBERT	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KAPLAN	ROBERT	LAS VEGAS	NV	\$134,066.25
KARRAR, ALI	Safety Study of DS-5565 for Treatment of Fibromyalgia	KARRAR	ALI	GRAND BLANC	MI	\$4,250.00
KARRAR, ALI KASS, ETHAN	Safety Study of DS-5565 for Treatment of Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks ir	KASS	ETHAN	CORAL SPRINGS	FL	\$2,029.03 \$7,872.93
KASS, ETHAN	Treatment of Pain Associated With Fibromyalgia	KASS	ETHAN	CORAL SPRINGS	FL	\$60,287.82
KELLEY, LEE	Treatment of Pain Associated With Fibromyalgia	KELLEY	LEE	SCOTTSDALE	AZ	\$1,725.93
KEMPERT, PAMELA	Phase 1 Pediatric PKPD Study					\$51.92
KESSLER FOUNDATION	Study to Evaluate the Efficacy, Safety, and	KIRSHBLUM	STEVEN	WEST ORANGE	NJ	\$6,013.87
KESTEN, JEFFREY KHALED, SAMER	Treatment of Pain Associated With Fibromyalgia (QuANTUM-R): An Open-label Study of Quizartinib	KESTEN KHALED	JEFFREY SAMER	GOLDEN DUARTE	CO CA	\$73,474.36 \$24,175.07
KHAN, AHTARAM	Safety Study of DS-5565 for Treatment of Fibromyalgia	KHAN	AHTARAM	PLANO	TX	\$6,500.00
KHAN, AHTARAM	Safety Study of DS-5565 for Treatment of Fibromyalgia					\$14,045.61
KHAN, AHTARAM	Safety Study of DS-5565 for Treatment of Fibromyalgia					\$525.33
KHRONUSOVA, YEKATERINA	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KHRONUSOVA	YEKATERINA	LAS VEGAS	NV	\$78,274.00
KHRONUSOVA, YEKATERINA KIVITZ, ALAN	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	KHRONUSOVA KIVITZ	YEKATERINA ALAN	LAS VEGAS DUNCANSVILLE	NV PA	\$544,112.83 \$45,975.05
KLEIN, THOMAS	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KLEIN	THOMAS	WICHITA	KS	\$24,967.80
KLEIN, THOMAS	Treatment of Pain Associated With Fibromyalgia	KLEIN	THOMAS	WICHITA	KS	\$88,563.26
KLUGE, RONICA	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KLUGE	RONICA	BONITA SPRINGS	FL	\$800.00
KLUGE, RONICA	Treatment of Pain Associated With Fibromyalgia	KLUGE	RONICA	BONITA SPRINGS	FL	\$38,958.70
KNUTSON, JAMES	Treatment of Pain Associated With Fibromyalgia	KNUTSON	JAMES	KIRKLAND	WA	\$58,335.20
KRAVITZ, ALAN KRAVITZ, ALAN	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	KRAVITZ KRAVITZ	ALAN	LYNDHURST LYNDHURST	ОН ОН	\$4,850.00 \$18,788.62
KRAVITZ, ALAN KRISHNASWAMY, KANNAPPAN	Safety Study of DS-5565 for Treatment of Fibromyalgia	KRAVITZ	KANNAPPAN	SEALY	TX	\$18,788.62 \$5,000.00
KRK MEDICAL RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KLYMIUK	ANDREW	DALLAS	TX	\$13,718.75
KRK MEDICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia	KLYMIUK	ANDREW	DALLAS	тх	\$15,019.31
KRK MEDICAL RESEARCH		KLYMIUK	ANDREW	DALLAS	тх	\$4,231.88
LACEY, DENNIS	An Open-Label Extension Study of DS-5565 for 52 Weeks in	LACEY	DENNIS	ATLANTA	GA	\$8,713.15
LACEY, DENNIS LACEY, DENNIS	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	LACEY	DENNIS	ATLANTA	GA	\$64,974.46 \$5,448.99
LACEY, DENNIS LAPEYRA, OLGA	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	LAPEYRA	OLGA	LAUDERHILL	FL	\$5,448.99 \$14,727.52
LAPP, CHARLES	Treatment of Pain Associated With Fibromyalgia	LAPP	CHARLES	CHARLOTTE	NC	\$9,314.34
LAWSON, JEFFREY	Edoxaban in Peripheral Arterial Disease ePAD					\$4,851.99
LAWSON, JEFFREY	Treatment of Pain Associated With Fibromyalgia	LAWSON	JEFFREY	GREENVILLE	SC	\$51,229.51
LEDERMAN, ELLIOT	Treatment of Pain Associated With Fibromyalgia	LEDERMAN	ELLIOT	BROOKLYN	NY	\$12,176.28
LEDO-SANCHEZ, GUSTAVO LEE, MARCUS	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks ir	LEDO-SANCHEZ LEE	GUSTAVO MARCUS	HIALEAH TULLAHOMA	FL TN	\$14,616.69 \$15,570.70
LEE, MARCUS	Treatment of Pain Associated With Fibromyalgia	LEE	MARCUS	TULLAHOMA	TN	\$15,570.70
LEGACY HEART CENTER	Edoxaban vs. Warfarin in Subjects Undergoing	MCKENZIE	MARCUS	PLANO	ТХ	\$89.50
LEHIGH VALLEY HOSPITAL	Edoxaban vs. Warfarin in Subjects Undergoing	HOANG	NGHIA	ALLENTOWN	PA	\$9,000.00
LESTER E COX MEDICAL CENTERS	Study to Evaluate the Efficacy, Safety, and	MACE	JOHN	SPRINGFIELD	MO	\$12,545.48
LEVINSON, LAWRENCE	An Open-Label Extension Study of DS-5565 for 52 Weeks in	LEVINSON	LAWRENCE	TIPTON	PA MD	\$33,272.64
LEVIS, MARK LIESVELD, JANE	(QuANTUM-R): An Open-label Study of Quizartinib (QuANTUM-R): An Open-label Study of Quizartinib	LEVIS	MARK JANE	BALTIMORE ROCHESTER	NY	\$20,522.50 \$2,560.00
LILLESTROL, MICHAEL	An Open-Label Extension Study of DS-5565 for 52 Weeks in	LILLESTOL	MICHAEL	FARGO	ND	\$23,765.53
LILLESTROL, MICHAEL	Treatment of Pain Associated With Fibromyalgia	LILLESTOL	MICHAEL	FARGO	ND	\$94,140.21
LILLO, JOSEPH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	LILLO	JOSEPH	SCOTTSDALE	AZ	\$47,723.85
LILLO, JOSEPH	Treatment of Pain Associated With Fibromyalgia	LILLO	JOSEPH	SCOTTSDALE	AZ	\$223,700.13
LIM, BORA LOAIZA-BONILLA, ARTURO	A Clinical Trial Using Patritumab or Placebo in Combination Study of Tivantinib in Subjects With Inoperable					\$89.80 \$1,446.77
LOAIZA-BONIELA, ARTORO	DS2248-A-U101	MIRSHAHIDI	HAMID	LOMA LINDA	CA	\$7,932.50
LOS AMIGOS RESEARCH & EDUCATION INSTITUTE INC.	Study to Evaluate the Efficacy, Safety, and	SCOTT	MICHAEL	DOWNEY	CA	\$500.00
LOUDERMILK, ERIC	Treatment of Pain Associated With Fibromyalgia	LOUDERMILK	ERIC	ANDERSON	SC	\$8,049.77
LUCAS, MEL	Treatment of Pain Associated With Fibromyalgia	LUCAS	MEL	FLORISSANT	MO	\$35,342.73
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD	Phase 1 Pediatric PKPD Study	JENG MABAQUIAO	MICHAEL ARTHUR	PALO ALTO	CA CA	\$13,356.00
MABAQUIAO, ARTHUR MAGEE REHABILITATION HOSPITAL	Treatment of Pain Associated With Fibromyalgia Study to Evaluate the Efficacy, Safety, and	FRIED	GUY	EL CAJON PHILADELPHIA	PA	\$57,681.00 \$8,774.48
MAIN RESEARCH ASSOCIATION LLC	DU176b-E-U210	NEDEAU	APRIL	LEWISTON	ME	\$3,764.00
MAIN RESEARCH ASSOCIATION LLC	Edoxaban vs. Warfarin in Subjects Undergoing	WEISS	ROBERT	AUBURN	ME	\$18,788.84
MALEMPATI, SRIKANTH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	MALEMPATI	SRIKANTH	CLEARWATER	FL	\$26,572.00
MANNING, RICKEY	Treatment of Pain Associated With Fibromyalgia	MANNING	RICKEY	KNOXVILLE	TN	\$77,001.88
MARCADIS, ABE MARCADIS, ABE	An Open-Label Extension Study of DS-5565 for 52 Weeks in	MARCADIS	ABE	WEST PALM BEACH WEST PALM BEACH	FL FL	\$11,505.22
MARCADIS, ABE MARTIN, RAQUEL	Treatment of Pain Associated With Fibromyalgia Edoxaban Cancer VTE	MARTIN	RAQUEL	TAMPA	FL	\$70,566.29 \$10,000.00
MAS, LUIS	Treatment of Pain Associated With Fibromyalgia	MAS	LUIS	MIAMI	FL	\$44,756.85
MASSACHUSETTS GENERAL HOSPITAL	DS2248-A-U101	SHAW	ALICE	BOSTON	MA	\$500.00
MASSACHUSETTSGENERALHOSP	DU176b-D-U311	ZWICKER	JEFFREY	BOSTON	MA	\$57.90
MAW, KELLI	Safety Study of DS-5565 for Treatment of Fibromyalgia Treatment of Pain Associated With Fibromyalgia	MAW	KELLI	BROOKSVILLE	FL	\$5,000.00
MAW, KELLI MCCAUL, KELLY	(QuANTUM-R): An Open-label Study of Quizartinib	MAW MCCAUL	KELLI KELLY	SIOUX FALLS	FL SD	\$108,642.05 \$1,060.00
MCCULLOUGH, ARTHUR	Study of Tivantinib in Subjects With Inoperable	MICCAUL	KELLI	SIOUXTALLS	30	\$1,380.00
MCGILL, LORA	An Open-Label Extension Study of DS-5565 for 52 Weeks in	MCGILL	LORA	MEMPHIS	TN	\$68,664.39
MCGILL, LORA	Treatment of Pain Associated With Fibromyalgia	MCGILL	LORA	MEMPHIS	TN	\$226,890.33
MCGILL, LORA	Treatment of Pain Associated With Fibromyalgia					\$14,000.00
MD ANDERSON - ORLANDO	DS2248-A-U101 A Deace 1 Multiple According Date Study of DS 2022h, an	TSENG	JENNIFER	ORLANDO	FL	\$500.00
MD ANDERSON CANCER CENTER MD ANDERSON CANCER CENTER	A Phase 1 Multiple Ascending Dose Study of DS-3032b, an DS3032-A-U101	HONG HONG	DAVID	HOUSTON HOUSTON	TX TX	\$20,368.69 \$40,423.08
MD ANDERSON CANCER CENTER	DS3032-A-0101 DS3032-A-U102	DINARDO	COURTNEY	HOUSTON	TX	\$236,547.00
MEDEIROS, BRUNO	(QuANTUM-R): An Open-label Study of Quizartinib	MEDEIROS	BRUNO	STANFORD	CA	\$19,237.60
MEDICAL CENTER OPHTHLMLGY ASSOCIATION	DS7080-A-U101	SINGER	MICHAEL	SAN ANTONIO	тх	\$16,281.13
MEDICAL COLLEGE OF VIRGINIA	Edoxaban vs. Warfarin in Subjects Undergoing	CHEIRIF	JORGE	DALLAS	TX	\$97.66
MEDICAL INVESTIGATIONS INC.	Treatment of Pain Associated With Fibromyalgia	BHAT	ANUPAMA	ROSEVILLE	CA	\$4,981.09
MEDICAL RESEARCH AND HEALTH EDUCATION MEDVIN CLINICAL RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	LISS METYAS	JONATHAN SAMY	COLUMBUS	GA CA	\$55,808.87 \$4,500.00
MEHRA, VIKRAM	Treatment of Pain Associated With Fibromyalgia	MEHRA	VIKRAM	HOUSTON	TX	\$33,411.84
MELLO, CURTIS	An Open-Label Extension Study of DS-5565 for 52 Weeks in	MELLO	CURTIS	NORTH DARTMOUTH	MA	\$12,852.00
MELLO, CURTIS	Treatment of Pain Associated With Fibromyalgia	MELLO	CURTIS	NORTH DARTMOUTH	MA	\$42,993.00
MEMORIAL SLOAN - KETTERING CANCER CENTER	A Phase 1 Multiple Ascending Dose Study of DS-3032b, an	GOUNDER	MRINAL	NEW YORK	NY	\$38,311.08
MEMORIAL SLOAN - KETTERING CANCER CENTER	DS3032-A-U101	GOUNDER	MRINAL	NEW YORK	NY	\$56,476.18
MERCY RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in		TIMOTHY	SAINT LOUIS	M0 M0	\$23,573.04 \$72,457.08
MERCY RESEARCH						
MERCY RESEARCH MERIDIAN CLINICAL RESEARCH LLC	Treatment of Pain Associated With Fibromyalgia	SMITH ESSINK	TIMOTHY BRANDON	SAINT LOUIS CREIGHTON	NE	\$3,750.00

Payee	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Total
MERIDIEN RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	Last Name HUFFMAN	First Name	TAMPA	Researcher FL	\$58.230.90
MERIDIEN RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in		CYNTHIA GIGI	ST PETERSBURG	FL	\$61,686.84
MERIDIEN RESEARCH	An open caser extension study of 55 5505 for 52 weeks in	ANDERSEN	JAMES	LAKELAND	FL	\$9,984.00
MERIDIEN RESEARCH		LEFEBVRE	GIGI	ST PETERSBURG	FL	\$4,000.00
MERIDIEN RESEARCH		MAW	KELLI	BROOKSVILLE	FL	\$10,998.00
MERIDIEN RESEARCH INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in	MAW	KELLI	BROOKSVILLE	FL	\$16,199.82
METROHEALTH SYSTEM DBA METROHEALTH MEDICAL METYAS, SAMY	Study to Evaluate the Efficacy, Safety, and Treatment of Pain Associated With Fibromyalgia	CLARIDGE METYAS	JEFFREY SAMY	CLEVELAND COVINA	OH CA	\$6,219.60 \$6,380.50
MEYER, CHRISTIAN	PLX3397 Phase 3 Study for Pigmented Villonodular	WETTAS	SAIVIT	COVINA	CA	\$1,201.21
MGPO VasCore	Edoxaban in Peripheral Arterial Disease ePAD	Jaff	Michael	Boston	MA	\$21,055.84
MHM SUPPORT SERVICES		SMITH	TIMOTHY	SAINT LOUIS	MO	\$21,519.20
MIAMI VALLEY HOSPITAL	Study to Evaluate the Efficacy, Safety, and	EKEH	AKPOFURE	DAYTON	OH	\$1,752.40
MICHIGAN COMP CANCER CENTER	PLX108-10	SCHUETZE	SCOTT	ANN ARBOR	MI	\$391.80
MICHIGAN HEAD PAIN & NEUROLOGY INSTITUTE MICHIGAN VASCULAR CENTER	DU176b-E-U210	PRESTEGAARD Malhotra	ALICIA Nitin	ANN ARBOR Flint	MI	\$12,375.00 \$2,434.50
MICHIGAN VASCOLAR CENTER MIDWEST CLINICAL RESEARCH CENTER LLC	001700-2-0210	DSOUZA	BERNADETTE	DAYTON	OH	\$3,000.00
MIZUTANI, WESLEY	Treatment of Pain Associated With Fibromyalgia	MIZUTANI	WESLEY	LONG BEACH	CA	\$10,413.86
MODUGU, SATHISH	Treatment of Pain Associated With Fibromyalgia	MODUGU	SATHISH	HARTSDALE	NY	\$18,937.80
MOE, PAUL	An Open-Label Extension Study of DS-5565 for 52 Weeks in	MOE	PAUL	INDIANAPOLIS	IN	\$13,176.00
MOE, PAUL	Treatment of Pain Associated With Fibromyalgia	MOE	PAUL	INDIANAPOLIS	IN	\$57,889.53
MONTANO, CHARLES MONTANO, CHARLES	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	MONTANO MONTANO	CHARLES CHARLES	CROMWELL	ст ст	\$16,135.98 \$49,185.76
MONTEFIORE MEDICAL CENTER	ARQ197	SCHWARTZ	JONATHAN	PORTLAND	OR	\$325.64
MONTEFIORE MEDICAL CENTER	Study of Tivantinib in Subjects With Inoperable	SCHWARTZ	JONATHAN	PORTLAND	OR	\$305.78
MONTGOMERY, RICHARD	Treatment of Pain Associated With Fibromyalgia	MONTGOMERY	RICHARD	WINSTONSALEM	NC	\$35,475.00
MOUNT SINAI HOSPITAL	PLX108-10	MAKI	ROBERT	NEW YORK	NY	\$410.50
MOUNT SINAI MEDICAL CENTER	DU176b-E-U210	VOUYOUKA	AGELIKI	NEW YORK	NY	\$1,827.20
MOUNT SINAI MEDICAL CENTER	Edoxaban in Peripheral Arterial Disease ePAD	VOUYOUKA	AGELIKI	NEW YORK	NY	\$500.00
MOUNTAIN VIEW CLINICAL RESEARCH - GREER	An Open-Label Extension Study of DS-5565 for 52 Weeks in	BALLARD	THOMAS	GREER	SC	\$75,067.30
MURTHY, RASHMI NAEL, SIAVASH	A Clinical Trial Using Patritumab or Placebo in Combination Treatment of Pain Associated With Fibromyalgia	NAEL	SIAVASH	OKLAHOMA CITY	ОК	\$89.80 \$54,148.96
NAND, CHETA	An Open-Label Extension Study of DS-5565 for 52 Weeks in	NAND	CHETA	KENNEWICK	WA	\$4,750.00
NAND, CHETA	Treatment of Pain Associated With Fibromyalgia	NAND	CHETA	KENNEWICK	WA	\$5,000.00
NASEERUDDIN, SYED	Treatment of Pain Associated With Fibromyalgia	NASEERUDDIN	SYED	SAINT CLOUD	FL	\$30,364.96
NATIONAL CLINICAL RESEARCH - RICHMOND INC.	Treatment of Pain Associated With Fibromyalgia	HOEKSTRA	JOHN	RICHMOND	VA	\$47,433.36
NEBRASKA METHODIST HOSPITAL	TIVANTINIB	LANGDON	ROBERT	OMAHA	NE	\$7,461.68
NEMOURS CHILDREN'S HOSPITAL ORLANDO	Phase 1 Pediatric PKPD Study	GORDON	PAUL	ORLANDO	FL	\$4,750.00
NEUROLOGY CENTER OF OKLAHOMA NEUROLOGY CLINICAL RESEARCH INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in	CONNOR SINGER	GREGORY RICHARD	TULSA PEMBROKE PINES	OK FL	\$4,599.90 \$2,000.00
NEUROLOGY CLINICAL RESEARCH INC.	Treatment of Pain Associated With Fibromyalgia	GILSON	NOAH	WEST LONG BRANCH	NJ	\$1,314.00
NEUTEL, JOEL	Treatment of Pain Associated With Fibromyalgia	NEUTEL	JOEL	TUSTIN	CA	\$1,505.33
NEW ORLEANS CENTER FOR CLINICAL RESEARCH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	VARGAS	RAMON	KENNER	LA	\$9,637.65
NEW ORLEANS CENTER FOR CLINICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia	VARGAS	RAMON	KENNER	LA	\$50,140.10
NEW YORK PRESBYTERIAN HOSPITAL	DU176b-E-U210	BAJAKIAN	DANIELLE	NEW YORK	NY	\$2,978.99
NGUYEN, QUAN	Study of DS-7080a for the Treatment of Neovascular Age-	WOYCH WHEE	MADY		011	\$1,307.24
NORTH STAR MEDICAL RESEARCH LLC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	WOYSHVILLE	MARK	MIDDLEBURG HEIGHTS	ОН	\$8,500.00
NORTH, JAMES	Pain Associated With Fibromyalgia	NORTH	JAMES	WINSTON SALEM	NC	\$16,576.47
NORTH, JAMES	Treatment of Pain Associated With Fibromyalgia	NORTH	JAMES	WINSTON SALEM	NC	\$57,117.47
NORTHERN CALIFORNIA RESEARCH		YOUNG	DOUGLAS	SACRAMENTO	CA	\$1,000.00
NORTHSIDE HOSPITAL	A Phase 3, Randomized, Double-Blind, Placebo-Controlled	SALEH	MANSOOR	SANDY SPRINGS	GA	\$1,899.00
NORTHSIDE HOSPITAL	TIVANTINIB	SALEH	MANSOOR	SANDY SPRINGS	GA	\$949.50
NORTHWEST CLINICAL RESEARCH CENTER NORTHWEST CLINICAL RESEARCH CENTER	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	KHAN KHAN	ARIFULLA	BELLEVUE BELLEVUE	WA WA	\$32,443.91 \$208,350.24
NORTHWEST CLINICAE RESEARCH CENTER	An Open-Label Extension Study of DS-5565 for 52 Weeks in		THOMAS	CHICAGO	IL.	\$11,000.00
NORTHWESTERN UNIVERSITY	Treatment of Pain Associated With Fibromyalgia	SCHNITZER	THOMAS	CHICAGO	IL	\$132,619.86
NORTON CANCER INSTITUTE	Study of Patritumab in Combination With Study of	HAMM	JOHN	LOUISVILLE	KY	\$14,040.00
NORWOOD, PAUL	An Open-Label Extension Study of DS-5565 for 52 Weeks in	NORWOOD	PAUL	FRESNO	CA	\$80,433.80
NUSSDORFER, THOMAS	An Open-Label Extension Study of DS-5565 for 52 Weeks in	NUSSDORFER	THOMAS	TRAVERSE CITY	MI	\$3,939.21
NUSSDORFER, THOMAS	Treatment of Pain Associated With Fibromyalgia	NUSSDORFER	THOMAS	TRAVERSE CITY	MI	\$33,716.61
OCHSNER MEDICAL CENTER JEFFSN HIGHWAY OHIO HEALTH RESEARCH INSTITUTE	DU176b-E-U210 DU176b-E-U210	OSINBOWALE PHILLIPS	OLUSEGUN JOHN	NEW ORLEANS COLUMBUS	LA OH	\$3,669.20 \$1,968.40
OHIO REALTH RESEARCH INSTITUTE	DU176b-D-U311	WANG	TZU-FEI	COLUMBUS	ОН	\$62.50
OKUNO, SCOTT	PLX3397 Phase 3 Study for Pigmented Villonodular					\$2,483.34
OLDFIELD, CHRISTOPHER	An Open-Label Extension Study of DS-5565 for 52 Weeks in		CHRISTOPHER	SAVANNAH	GA	\$11,648.30
OLDFIELD, CHRISTOPHER	Treatment of Pain Associated With Fibromyalgia	OLDFIELD	CHRISTOPHER	SAVANNAH	GA	\$36,541.61
OMEGA MEDICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia	FRIED	DAVID	EAST GREENWICH	RI	\$19,140.63
OMEGA RESEARCH CONSULTANTS LLC OMEGA RESEARCH CONSULTANTS LLC	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	KAPIL KAPIL	SANJIV SANJIV	LAKE MARY LAKE MARY	FL	\$6,394.23 \$41,470.79
OMEGA RESEARCH CONSULTANTS LLC		KAPIL	SANJIV	LAKE MARY	FL	\$5,000.00
ONSITE CLINICAL SOLUTIONS LLC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KEATING	WILLIAM	DAWSONVILLE	GA	\$6,245.10
ONSITE CLINICAL SOLUTIONS LLC	Treatment of Pain Associated With Fibromyalgia	KEATING	WILLIAM	DAWSONVILLE	GA	\$40,785.80
ONSITE CLINICAL SOLUTIONS LLC		KEATING	WILLIAM	DAWSONVILLE	GA	\$4,750.00
OPHTHALMIC CONSULTANTS BOSTON	DS7080-A-U101	HEIER	JEFFREY	BOSTON	MA	\$3,557.19
OPTIMUM CLINICAL RESEARCH INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in	RHUDY	JACKSON	SALT LAKE CITY	UT	\$69,466.41
OPTIMUM CLINICAL RESEARCH INC. ORANGE COUNTY NEUROPSYCHIATRIC RESEARCH CENTER	Treatment of Pain Associated With Fibromyalgia	RHUDY CHUEH	JACKSON DANIEL	SALT LAKE CITY ORANGE	UT CA	\$4,000.00 \$44,267.37
OREGON CENTER FOR CLINICAL INVESTIGATIONS INC.		ESSINK	BEAL	SALEM	OR	\$4,000.00
OREGON CENTER FOR CLINICAL INVESTIGATIONS INC.		HORWITZ	ALEXANDER	SALEM	OR	\$8,000.00
OREGON HEALTH & SCIENCE UNIVERSITY	DS2248-A-U101	CETNAR	JEREMY	PORTLAND	OR	\$5,753.88
OREGON HEALTH & SCIENCE UNIVERSITY	PLX108-10	RYAN	CHRISTOPHER	PORTLAND	OR	\$17,425.00
ORTHOPEDICS RESEARCH INSTITUTE	Treatment of Pain Associated With Fibromyalgia	WEINSTEIN	DEBRA	BOYNTON BEACH	FL	\$35,304.64
		OSKOOILAR	NADER NADER	NEWPORT BEACH NEWPORT BEACH	CA CA	\$5,362.20 \$53,292.60
OSKOOILAR, NADER	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia			INC WE ON L DEACH		\$53,292.60 \$266.64
OSKOOILAR, NADER	Treatment of Pain Associated With Fibromyalgia	OSKOOILAR TORBEY			OH	
	Treatment of Pain Associated With Fibromyalgia DS1040-A-U103	TORBEY LORCH	MICHEL	COLUMBUS BRANDON	OH FL	
OSKOOILAR, NADER OSU WEXNER MEDICAL CENTER	Treatment of Pain Associated With Fibromyalgia	TORBEY	MICHEL	COLUMBUS		\$3,300.00 \$43,540.68
OSKOOILAR, NADER OSU WEXNER MEDICAL CENTER PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC.	Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	TORBEY LORCH LORCH LORCH	MICHEL DANIEL DANIEL DANIEL	COLUMBUS BRANDON BRANDON BRANDON	FL FL FL	\$3,300.00 \$43,540.68 \$4,000.00
OSKOOILAR, NADER OSU WEXNER MEDICAL CENTER PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PAG CLINICAL RESEARCH INC. PACIFIC CLINICAL RESEARCH MEDICAL GROUP	Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	TORBEY LORCH LORCH LORCH ARIAS	MICHEL DANIEL DANIEL DANIEL AI-LI	COLUMBUS BRANDON BRANDON BRANDON PATTON	FL FL FL CA	\$3,300.00 \$43,540.68 \$4,000.00 \$2,750.00
OSKOOILAR, NADER OSU WEXNER MEDICAL CENTER PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PACIFIC CLINICAL RESRCH MEDICAL GROUP PACIFIC CLINICAL RESRCH MEDICAL GROUP	Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	TORBEY LORCH LORCH LORCH ARIAS ARIAS	MICHEL DANIEL DANIEL DANIEL AI-LI AI-LI	COLUMBUS BRANDON BRANDON BRANDON PATTON PATTON	FL FL CA CA	\$3,300.00 \$43,540.68 \$4,000.00 \$2,750.00 \$33,912.12
OSKOOILAR, NADER OSU WEXNER MEDICAL CENTER PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PACIFIC CLINICAL RESRCH MEDICAL GROUP PACIFIC CLINICAL RESRCH MEDICAL GROUP PACIFIC CRESEARCH PARNTERS LLC	Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	TORBEY LORCH LORCH LORCH ARIAS ARIAS GLICK	MICHEL DANIEL DANIEL DANIEL AI-LI AI-LI IRA	COLUMBUS BRANDON BRANDON BRANDON PATTON PATTON STANFORD	FL FL FL CA CA CA	\$3,300.00 \$43,540.68 \$4,000.00 \$2,750.00 \$33,912.12 \$4,000.00
OSKOOILAR, NADER OSU WEXNER MEDICAL CENTER PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PACIFIC CLINICAL RESRCH MEDICAL GROUP PACIFIC CLINICAL RESRCH MEDICAL GROUP PACIFIC RESEARCH PARNTERS LLC PAHLAVAN, PEYMAN	Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	TORBEY LORCH LORCH LORCH ARIAS ARIAS GLICK PAHLAVAN	MICHEL DANIEL DANIEL DANIEL AI-LI IRA PEYMAN	COLUMBUS BRANDON BRANDON BRANDON PATTON PATTON STANFORD MELROSE PARK	FL FL CA CA CA IL	\$3,300.00 \$43,540.68 \$4,000.00 \$2,750.00 \$33,912.12 \$4,000.00 \$44,884.80
OSKOOILAR, NADER OSU WEXNER MEDICAL CENTER PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PAB CLINICAL RESEARCH INC. PACIFIC CLINICAL RESRCH MEDICAL GROUP PACIFIC CLINICAL RESRCH MEDICAL GROUP PACIFIC CRESEARCH PARNTERS LLC	Treatment of Pain Associated With Fibromyalgia DS1040-A-U103 An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	TORBEY LORCH LORCH LORCH ARIAS ARIAS GLICK	MICHEL DANIEL DANIEL DANIEL AI-LI AI-LI IRA	COLUMBUS BRANDON BRANDON BRANDON PATTON PATTON STANFORD	FL FL FL CA CA CA	\$3,300.00 \$43,540.68 \$4,000.00 \$2,750.00 \$33,912.12 \$4,000.00

Payee	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Total
PALMETTO CLINICAL TRIAL SERVICES LLC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	Last Name LAWSON	First Name JEFFREY	GREENVILLE	Researcher SC	\$3,645.02
PALMETTO CLINICAL TRIAL SERVICES LLC		LAWSON	JEFFREY	GREENVILLE	SC	\$8,703.04
PALMETTO PRIMARY CARE PHYSICIANS		GROSSMAN	COLBY	SUMMERVILLE	SC	\$7,900.00
	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	DIAB PATAK	ISAM RAM	MIDDLEBURG HTS NORTHRIDGE	OH CA	\$31,918.83 \$22,171.50
	Study to Evaluate the Safety, Tolerability and	PATAK	NAIVI	NORTHRIDGE	CA	\$6,970.26
PATRICK, KYLE	Treatment of Pain Associated With Fibromyalgia	PATRICK	KYLE	SCOTTSDALE	AZ	\$14,644.80
	Phase 1 Pediatric PKPD Study	FREIBERG	ANDREW	HERSHEY	PA	\$3,600.00
	Treatment of Pain Associated With Fibromyalgia	PENN	SARA	BOSTON	MA	\$48,463.70
PERL, ALEXANDER	(QuANTUM-R): An Open-label Study of Quizartinib	PERL	ALEXANDER	PHILADELPHIA	PA	\$50,901.00
	Quizartinib With Standard of Care Chemotherapy and as An Open-Label Extension Study of DS-5565 for 52 Weeks in	RUANE	PETER	LOS ANGELES	CA	\$9,307.25 \$57,255.66
	Safety Study of DS-5565 for Treatment of Fibromyalgia	JARRETT	THOMAS	HIGH POINT	NC	\$5,500.00
PHARMACOLOGY RESEARCH INSTITUTE		DE FRANCISCO	DON	NEWPORT BEACH	CA	\$2,310.00
PHARMACOLOGY RESEARCH INSTITUTE		OSKOOILAR	NADER	NEWPORT BEACH	CA	\$2,772.00
		PEYTON	MARVIN	OKLAHOMA CITY	ОК	\$7,489.80
	Treatment of Pain Associated With Fibromyalgia	BOOMERSHINE	CHAD	NASHVILLE	TN	\$32,928.58
	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	MURRAY	ALEXANDER ALEXANDER	GREENSBORO GREENSBORO	NC NC	\$23,877.45 \$115,654.85
	An Open-Label Extension Study of DS-5565 for 52 Weeks in	PHILLIPS	CHRISTOPHER	PADUCAH	KY	\$68,173.20
PHOENIX CARDIOVASCULAR RESEARCH GROUP	Edoxaban vs. Warfarin in Subjects Undergoing	BAHU	MARWAN	PHOENIX	AZ	\$7,642.53
PIONEER RESEARCH SOLUTIONS INC.	Safety Study of DS-5565 for Treatment of Fibromyalgia	BHUCHAR	SUBODH	SUGAR LAND	тх	\$4,000.00
PMG RESEARCH INC.		BURACK	DAVID	ROCK HILL	SC	\$1,000.00
	Treatment of Pain Associated With Fibromyalgia	OLDS	SHELBY	BRISTOL	TN	\$111,344.64
	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	BURACK	DAVID	ROCK HILL	SC	\$30,782.82
PMG RESEARCH OF CHARLOTTE LLC PMG RESEARCH OF KNOXVILLE	An Open-Label Extension Study of DS-5565 for 52 Weeks in	RAAD	GEORGE PAUL	CHARLOTTE KNOXVILLE	NC TN	\$149,104.90 \$17,063.44
	Treatment of Pain Associated With Fibromyalgia	WAKEFIELD	PAUL	KNOXVILLE	TN	\$117,138.09
PMG RESEARCH OF SALISBURY	Treatment of Pain Associated With Fibromyagia	PATEL	RAKESH	SALISBURY	NC	\$79,832.73
PMG RESEARCH OF WILMINGTON LLC	DU176b-E-U210	CANNON	KEVIN	WILMINGTON	NC	\$1,500.00
	Treatment of Pain Associated With Fibromyalgia	WILSON	JONATHAN	HICKORY	NC	\$139,013.93
POLLACK, KENNETH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	POLLACK	KENNETH	WEST DES MOINES	IA	\$88,903.29
POWELL, BAYARD PRESTEGAARD, ALICIA	(QuANTUM-R): An Open-label Study of Quizartinib Treatment of Pain Associated With Fibromyalgia	POWELL PRESTEGAARD	BAYARD ALICIA	WINSTON SALEM ANN ARBOR	NC MI	\$20,681.95 \$44,943.75
	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	TRESTEGAARD	ALICIA		1411	\$44,943.75 \$4,266.00
QUALITY CLINICAL RESEARCH INC.		DUNN	MICHAEL	OMAHA	NE	\$10,280.14
	Study to Evaluate the Efficacy, Safety, and	CHANG	CHERYLEE	HONOLULU	н	\$37,868.81
R/D CLINICAL RESEARCH INC.		FEAVER	BRIAN	LAKE JACKSON	тх	\$6,750.00
	Treatment of Pain Associated With Fibromyalgia	DAVIS	BETHANY	ATLANTA	GA	\$18,743.83
RADIANT RESEARCH INC.	Treatment of Pain Associated With Fibromyalgia	ELLISON	WILLIAM	GREER	SC	\$30,171.19
	Treatment of Pain Associated With Fibromyalgia Treatment of Pain Associated With Fibromyalgia	JENNINGS KOPP	WILLIAM JAMES	SAN ANTONIO ANDERSON	TX SC	\$27,416.37 \$22,106.86
	Treatment of Pain Associated With Fibromyagia	TEJADA	ALBERT	PHOENIX	AZ	\$20,285.71
RADIANT RESEARCH INC.		ELLISON	WILLIAM	GREER	SC	\$5,000.00
RADIANT RESEARCH INC.		KOPP	JAMES	ANDERSON	SC	\$5,000.00
RADIANT RESEARCH INC.		TEJADA	ALBERT	PHOENIX	AZ	\$5,000.00
	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	DEMETERCO-BERGGREN	CARLA	SAN DIEGO	CA	\$18,936.00
	Phase 1 Pediatric PKPD Study Study of DS-7080a for the Treatment of Neovascular Age-	TREMOULET	ADRIANA	SAN DIEGO	CA	\$6,705.00 \$1,349.49
	Treatment of Pain Associated With Fibromyalgia	RAIKHEL	MARINA	LOMITA	CA	\$1,349.49
RAO, T HEMANTH	An Open-Label Extension Study of DS-5565 for 52 Weeks in	RAO	T HEMANTH	CHARLOTTE	NC	\$8,229.94
RAPID CITY REGIONAL HOSPITAL	Edoxaban vs. Warfarin in Subjects Undergoing	AIREY	KELLY	RAPID CITY	SD	\$1,500.00
RAPID MEDICAL RESEARCH INC.		KRAVITZ	ALAN	LYNDHURST	ОН	\$8,500.00
	An Open-Label Extension Study of DS-5565 for 52 Weeks in	REED	LARRY	ALTON	IL	\$75,798.28
	To Determine Mechanisms of action of the Daiichi Sankyo To Determine Mechanisms of action of the Daiichi Sankyo	LEVI	MOSHE MOSHE	AURORA AURORA	CO CO	\$29,333.00 \$22,680.00
REGENTS OF THE UNIVERSITY OF MICHIGAN	PLX108-10	SCHUETZE	SCOTT	ANN ARBOR	мі	\$32,901.86
	An Open-Label Extension Study of DS-5565 for 52 Weeks in		QAISER	HOUSTON	тх	\$4,500.00
REHMAN, QAISER	Treatment of Pain Associated With Fibromyalgia	REHMAN	QAISER	HOUSTON	ТΧ	\$21,378.40
	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	REINER	BARRY	BALTIMORE	MD	\$21,280.00
	An Open-Label Extension Study of DS-5565 for 52 Weeks in		SIDNEY	OCALA	FL	\$69,062.87
	Treatment of Pain Associated With Fibromyalgia Edoxaban vs. Warfarin in Subjects Undergoing	CLEVINGER AMIN	SIDNEY MAHESH	OCALA CLEARWATER	FL	\$195,000.42 \$675.00
RESEARCH ALLIANCE INC. RETINA INSTITUTE OF CALIFORNIA	DS7080-A-U101	CHANG	TOM	PASADENA	FL CA	\$675.00 \$5,772.00
RETINA INSTITUTE OF CALIFORNIA	DS7080-A-U101	SAMUEL	MICHAEL	PASADENA	CA	\$15,402.13
RETINA INSTITUTE OF CLFNA	DS7080-A-U101	CHANG	TOM	PASADENA	CA	\$557.19
	DS7080-A-U101	BERGER	BRIAN	AUSTIN	ТΧ	\$3,557.19
	DS7080-A-U101	PATEL	HITENDRA	KANSAS CITY	MO	\$558.29
	DS7080-A-U101 DS7080-A-U101	RAHHAL DUGEL	FIRAS PRAVIN	LOS ANGELES PHOENIX	CA AZ	\$17,275.27 \$557.19
RETINAL RESEARCH INSTI RIBO RESEARCH LLC	DS7080-A-0101 An Open-Label Extension Study of DS-5565 for 52 Weeks in	PATEL	KASHYAP	ORMOND BEACH	AZ FL	\$557.19 \$61,016.40
RIBO RESEARCH LLC		PATEL	KASHYAP	ORMOND BEACH	FL	\$5,000.00
	Treatment of Pain Associated With Fibromyalgia	RICCI	DONATO	PORT ORANGE	FL	\$14,919.38
	An Open-Label Extension Study of DS-5565 for 52 Weeks in		RALPH	TULSA	ОК	\$6,781.52
	Treatment of Pain Associated With Fibromyalgia	RICHTER	RALPH	TULSA	ОК	\$28,943.99
RIEDEL, RICHARD	PLX3397 Phase 3 Study for Pigmented Villonodular	HOLE	CUCAN	ED CENTRE		\$1,302.17
	An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in		SUSAN IGNACIO	EDGEWATER HIALEAH	FL	\$4,150.24 \$5,650.31
RODRIGUEZ, IGNACIO RODRIGUEZ, IGNACIO	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	RODRIGUEZ	IGNACIO	HIALEAH	FL	\$5,650.31 \$48,998.95
	Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1				1 1	\$4,533.58
	PLX3397 Phase 3 Study for Pigmented Villonodular		<u> </u>			\$123.48
ROSS, DAVID	Treatment of Pain Associated With Fibromyalgia	ROSS	DAVID	PLANTATION	FL	\$14,341.74
ROWAN UNIVERSITY		JERMYN	RICHARD	STRATFORD	NJ	\$6,650.00
ROWAN UNIVERSITY SCHOOL OF OSTEOPATHIC MEDICINE	An Open-Label Extension Study of DS-5565 for 52 Weeks in	JERMYN	RICHARD	STRATFORD	NJ	\$2,530.00
DOWANI UNIVERSITY SCHOOL OF OFFENDATION	Treatment of Pain Associated With Fibromyalgia	JERMYN	RICHARD	STRATFORD	NJ	\$16,376.80 \$105.40
	, ,		1	1	NC	\$105.40
RUBENSTEIN, JAMES		RUBINO	JOHN	RALEIGH		
RUBENSTEIN, JAMES RUBINO, JOHN	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	RUBINO RUBINO	JOHN	RALEIGH RALEIGH	NC	\$170,568.20
RUBENSTEIN, JAMES RUBINO, JOHN RUBINO, JOHN	An Open-Label Extension Study of DS-5565 for 52 Weeks in	RUBINO				
RUBENSTEIN, JAMES RUBINO, JOHN RUBINO, JOHN RUDOLPH, LANCE RUDOLPH, LANCE	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	RUBINO	JOHN	RALEIGH	NC	\$170,568.20 \$19,397.18 \$70,723.81
RUBENSTEIN, JAMES RUBINO, JOHN RUBINO, JOHN RUDOLPH, LANCE RUDOLPH, LANCE RUFF, CHRISTIAN	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of	RUBINO RUDOLPH	JOHN LANCE	RALEIGH ALBUQUERQUE	NC NM	\$170,568.20 \$19,397.18 \$70,723.81 \$572.34
RUBENSTEIN, JAMES RUBINO, JOHN RUBINO, JOHN RUDOLPH, LANCE RUDOLPH, LANCE RUFF, CHRISTIAN RUFF, CHRISTIAN	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of Global Study to Assess the Safety and Effectiveness of	RUBINO RUDOLPH RUDOLPH	JOHN LANCE LANCE	RALEIGH ALBUQUERQUE ALBUQUERQUE	NC NM NM	\$170,568.20 \$19,397.18 \$70,723.81 \$572.34 \$102.00
RUBENSTEIN, JAMES RUBINO, JOHN RUDBINO, JOHN RUDOLPH, LANCE RUDOLPH, LANCE RUFF, CHRISTIAN RUFF, CHRISTIAN SAHAGIAN, ARIS	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia Global Study to Assess the Safety and Effectiveness of	RUBINO RUDOLPH RUDOLPH	JOHN LANCE	RALEIGH ALBUQUERQUE	NC NM	\$170,568.20 \$19,397.18 \$70,723.81 \$572.34

Payee	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Total
SAJAN, CHERIAN	Treatment of Pain Associated With Fibromyalgia	Last Name SAJAN	First Name CHERIAN	WINTER PARK	Researcher FL	\$18,616.66
SAJAN, CHERIAN SAMBUNARIS, ANGELO	An Open-Label Extension Study of DS-5565 for 52 Weeks in	SAJAN	ANGELO	ATLANTA	GA	\$18,567.04
SANCHEZ, MANUEL	An Open-Label Extension Study of DS-5565 for 52 Weeks in	SANCHEZ	MANUEL	HIALEAH	FL	\$41,265.95
SANCHEZ, MANUEL	Treatment of Pain Associated With Fibromyalgia	SANCHEZ	MANUEL	HIALEAH	FL	\$191,930.70
SARAH CANNON RESEARCH INSTITUTE LLC	A Phase 1 Multiple Ascending Dose Study of DS-3032b, an	BAUER	TODD	NASHVILLE	TN	\$1,234.00
SARAH CANNON RESEARCH INSTITUTE LLC	A Randomized, Placebo-Controlled, Phase 12 Study Of ARQ		LOWELL	FORT MYERS	FL	\$350.00
SARAH CANNON RESEARCH INSTITUTE LLC SARAH CANNON RESEARCH INSTITUTE LLC	DS3032-A-U101 DS8273-A-U101	BAUER BENDELL	TODD JOHANNA	NASHVILLE NASHVILLE	TN TN	\$49,081.41 \$80,710.80
SARAH CANNON RESEARCH INSTITUTE LLC	Edoxaban vs. Warfarin in Subjects Undergoing	HO	ANDY	WESTMINSTER	CA	\$5,535.64
SARAH CANNON RESEARCH INSTITUTE LLC	Open-label Study of DS-8273a to Assess Its Safety and	BENDELL	JOHANNA	NASHVILLE	TN	\$12,487.00
SARAH CANNON RESEARCH INSTITUTE LLC	Study of Patritumab in Combination With Study of	SPIGEL	DAVID	NASHVILLE	TN	\$66,339.08
SARAH CANNON RESEARCH INSTITUTE LLC	TIVANTINIB	BENDELL	JOHANNA	NASHVILLE	TN	\$49,723.53
SARAH CANNON RESEARCH INSTITUTE LLC	TIVANTINIB	HART	LOWELL	FORT MYERS	FL	\$31,216.30
SARAH CANNON RESEARCH INSTITUTE LLC SARAH CANNON RESEARCH INSTITUTE LLC	TIVANTINIB U31287-U-105	KUDRIK MOORE	FRED KATHLEEN	COLUMBIA OKLAHOMA CITY	SC OK	\$1,000.00 \$71,054.48
SARAH CANNON RESEARCH INSTITUTE LLC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	JOHNSON	MICHAEL	GAINESVILLE	FL	\$5,742.17
SARKIS CLINICAL TRIALS	Treatment of Pain Associated With Fibromyalgia	JOHNSON	MICHAEL	GAINESVILLE	FL	\$48,825.90
SCHEIN, PHILIP	Study to Evaluate the Safety, Tolerability and					\$3,485.00
SCHILLER, GARY	(QuANTUM-R): An Open-label Study of Quizartinib	SCHILLER	GARY	LOS ANGELES	CA	\$49,828.68
SCHWARTZ, JONATHAN	Study of Tivantinib in Subjects With Inoperable				$ \longrightarrow $	\$1,430.52
SCHWARTZ, LAWRENCE	PLX3397 Phase 3 Study for Pigmented Villonodular		DANIEL	SCOTTEDALE	AZ	\$66.44
SCOTTSDALE HEALTHCARE HOSPITALS DBA SCOTTSDALE HEALTHCARE HOSPITALS DBA	A First-in-human Study to Evaluate the Safety, Tolerability DS6051-A-U101	VON HOFF BORAZANCI	DANIEL ERKUT	SCOTTSDALE SHREVEPORT	AZ LA	\$23,419.12 \$86,893.36
SCOTTSDALE HEALTHCARE HOSPITALS DBA	DS6051-A-0101 DS6051-A-U101	VON HOFF	DANIEL	SCOTTSDALE	AZ	\$10,189.80
SDS CLINICAL TRIALS INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in	SCHREIBER	ANDREW	COSTA MESA	CA	\$27,623.36
SDS CLINICAL TRIALS INC.	Treatment of Pain Associated With Fibromyalgia	SCHREIBER	ANDREW	COSTA MESA	CA	\$55,919.40
SDS CLINICAL TRIALS INC.		SCHREIBER	ANDREW	COSTA MESA	CA	\$4,500.00
SEALY URGENT CARE CENTER AND MEDICAL CLINIC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KRISHNASWAMY	KANNAPPAN	SEALY	TX	\$6,275.08
SEALY URGENT CARE CENTER AND MEDICAL CLINIC	Treatment of Pain Associated With Fibromyalgia	KRISHNASWAMY	KANNAPPAN	SEALY	TX	\$31,969.01
SEATTLE CANCER CARE ALLIANCE SEATTLE CANCER CARE ALLIANCE	ARQ197 Study of Tivantinib in Subjects With Inoperable	HARRIS HARRIS	WILLIAM	SEATTLE	WA	\$82.40 \$598.42
SEATTLE CANCER CARE ALLIANCE	TC00001950	HARRIS	WILLIAM	SEATTLE	WA	\$598.42 \$425.58
SEITER, KAREN	(QuANTUM-R): An Open-label Study of Quizartinib	SEITER	KAREN	HAWTHORNE	NY	\$425.58
SELAM, JEAN-LOUIS	An Open-Label Extension Study of DS-5565 for 52 Weeks in	SELAM	JEAN LOUIS	TUSTIN	CA	\$228,578.09
SERRG SAVANNAH INC.	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KINGSLEY	JEFFREY	COLUMBUS	GA	\$3,900.00
SERRG SAVANNAH INC.	Treatment of Pain Associated With Fibromyalgia	KINGSLEY	JEFFREY	COLUMBUS	GA	\$175,157.76
SERRG SAVANNAH INC.		KINGSLEY	JEFFREY	COLUMBUS	GA	\$7,900.00
SHAY, MARC	Treatment of Pain Associated With Fibromyalgia	SHAY	MARC	AMESBURY	MA	\$30,474.81
SHEEHAN, DAVID	DS-5565 Phase III Study for Diabetic Peripheral	40015	DAV//D	AT! ANTA	<u></u>	\$2,202.66
SHEPHERD CENTER INC. SHERGY, WILLIAM	Study to Evaluate the Efficacy, Safety, and Treatment of Pain Associated With Fibromyalgia	APPLE SHERGY	DAVID WILLIAM	ATLANTA HUNTSVILLE	GA AL	\$600.00 \$8,862.30
SHIWACH, RAJINDER	Treatment of Pain Associated With Fibromyalgia	SHIWACH	RAJINDER	DESOTO	TX	\$3,050.45
SIEGELMAN, EVAN	A Phase 3, Randomized, Double-Blind Study of Tivantinib	SIEGELMAN	EVAN	PHILADELPHIA	PA	\$11,025.00
SIEGELMAN, EVAN	TIVANTINIB	SIEGELMAN	EVAN	PHILADELPHIA	PA	\$8,095.50
SINGER, MICHAEL	Study of DS-7080a for the Treatment of Neovascular Age-					\$1,420.24
SITAR, STEVE	Safety Study of DS-5565 for Treatment of Fibromyalgia					\$1,500.22
SITAR, STEVE	Treatment of Pain Associated With Fibromyalgia	SITAR	STEVE	ANAHEIM	CA	\$5,862.23
SLOAN - KETTERING INSTITUTE FOR CANCER SOCINSKI, MARK	PLX108-10 A Clinical Trial Using Patritumab or Placebo in Combination	ТАР	WILLIAM	NEW YORK	NY	\$26,123.50 \$5,429.77
SOCINSKI, MARK	Study of Patritumab in Combination With Study of				+	\$6,195.33
SOEFJE, SHERRY	An Open-Label Extension Study of DS-5565 for 52 Weeks in	SOEFJE	SHERRY	OCEANSIDE	CA	\$2,304.90
SOEFJE, SHERRY	Treatment of Pain Associated With Fibromyalgia	SOEFJE	SHERRY	OCEANSIDE	CA	\$54,660.21
SOUTH BROWARD HOSPITAL DISTRICT	Study to Evaluate the Efficacy, Safety, and	CARRILLO	EDDY	HOLLYWOOD	FL	\$2,050.00
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS	DS6051-A-U101	PAPADOPOULOS	KYRIAKOS	SAN ANTONIO	тх	\$214,259.39
SOUTHWEST RHEUMATOLOGY RESEARCH LLC		SINGHAL	ATUL	MESQUITE	TX	\$3,500.00
SPIERINGS, EGILIUS SPIERINGS, EGILIUS	An Open-Label Extension Study of DS-5565 for 52 Weeks in Safety Study of DS-5565 for Treatment of Fibromyalgia	SPIERINGS	EGILIUS	WELLESLEY HILLS	MA	\$125,202.32 \$1,365.87
SPIERINGS, EGILIOS SPIRE SCIENCE INC.	PLX3397 Phase 3 Study for Pigmented Villonodular	PETERFY	CHARLES	KENTFIELD	CA	\$2,010.00
ST BARNABAS MEDICAL CENTER	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	BRENNER	DENNIS	WEST ORANGE	NJ	\$1,500.00
ST JUDE CHILDREN'S RESEARCH HOSPITAL INC.	Phase 1 Pediatric PKPD Study	ESTEPP	JEREMIE	MEMPHIS	TN	\$31,882.40
ST LUKE'S REGIONAL	Edoxaban vs. Warfarin in Subjects Undergoing	DACCARETT	MARCOS	BOISE	ID	\$4,000.00
STANFORD UNIVERSITY	PLX108-10	GANJOO	KRISTEN	STANFORD	CA	\$19,212.00
STANFORD UNIVERSITY MEDICAL CENTER RAD/ONC	PLX108-10	GANJOO	KRISTEN	STANFORD	CA	\$297.50
STONE, RICHARD STRICKLAND, STEPHEN	(QuANTUM-R): An Open-label Study of Quizartinib (QuANTUM-R): An Open-label Study of Quizartinib	STONE STRICKLAND	RICHARD STEPHEN	BOSTON	MA TN	\$16,625.00 \$42,579.44
STRICKLAND, STEPHEN STRICKLAND, STEPHEN	Quizartinib With Standard of Care Chemotherapy and as	STRICKLAIND	SIEFTIEN			\$42,579.44 \$1,118.71
STUDYOPS INC.	and the second s	BOKARIUS	VLADIMIR	RICHMOND	CA	\$8,500.00
SUBURBAN RESEARCH ASSOCIATION	Treatment of Pain Associated With Fibromyalgia	HATTI	SHIVKUMAR	MEDIA	PA	\$31,329.85
SUMMIT RESEARCH NETWORK MANAGEMENT INC.	Treatment of Pain Associated With Fibromyalgia	COLVARD	MARYANN	PORTLAND	OR	\$108,370.64
SUMMIT RESEARCH NETWORK MANAGEMENT INC.	Treatment of Pain Associated With Fibromyalgia	WALTMAN	CLAIRE	SEATTLE	WA	\$63,579.60
SUMMIT RESEARCH NETWORK MANAGEMENT INC.	An Onen Label Extension Study of DC EECE for E2 W. J. J.	WALTMAN	CLAIRE	SEATTLE	WA	\$8,184.00
SUNCOAST CLINICAL RESEARCH INC NEW PORT RICHEY SUNCOAST CLINICAL RESEARCH INC NEW PORT RICHEY	An Open-Label Extension Study of DS-5565 for 52 Weeks in An Open-Label Extension Study of DS-5565 for 52 Weeks in	COHEN PLEVIN	LISA SANFORD	PALM HARBOR PALM HARBOR	FL	\$11,298.56 \$16,715.52
SUNCOAST CLINICAL RESEARCH INC NEW PORT RICHEY SUNRISE MEDICAL RESEARCH INC.	Chi Open-Laber Extension Study of DS-SS65 for SZ Weeks in	ROSS	DAVID	PALM HARBOR PLANTATION	FL	\$16,715.52 \$4,000.00
SUNSTONE MEDICAL RESEARCH LLC	1	ALFTINE	CHRISTOPHER	MEDFORD	OR	\$15,256.25
SWEDISH CANCER INSTITUTE	DS2248-A-U101	WEST	HOWARD	SEATTLE	WA	\$8,897.70
SWEDISH HEALTH SERVICES	Study of Patritumab in Combination With Study of	WEST	HOWARD	SEATTLE	WA	\$15,046.02
SZEFLER, STANLEY	PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed			<u> </u>	\downarrow	\$53.94
TAMAYO, RAUL	Treatment of Pain Associated With Fibromyalgia	TAMAYO	RAUL	CORAL GABLES	FL	\$36,196.55
TAP, WILLIAM TAP, WILLIAM	I-SPY 2 TRIAL Neoadjuvant and Personalized Adaptive Neoadjuvant and Personalized Adaptive Novel Agents to		<u> </u>	<u> </u>	┼───┼	\$5,060.00 \$406.38
TAP, WILLIAM TAP, WILLIAM	PLX3397 Phase 3 Study for Pigmented Villonodular		1	<u>†</u>	┼───┼	\$406.38 \$1,002.84
TAP, WILLIAM TAP, WILLIAM	PLX3397 Phase 3 Study for Pigmented Villonodular		1	1	<u>∤</u> ───┤	\$1,437.55
TAPSON, VICTOR	DS 1040 B U107 PE		1			\$24.47
TARHEEL CLINICAL RESEARCH		VYAS	PANKAJKUMAR	BENSON	NC	\$750.00
TARLETON, GREGORY	Treatment of Pain Associated With Fibromyalgia	TARLETON	GREGORY	WINSTONSALEM	NC	\$18,027.42
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM	Study to Evaluate the Efficacy, Safety, and	WEAVER	MICHAEL	PHILADELPHIA	PA	\$3,559.68
TESSER, JOHN	Treatment of Pain Associated With Fibromyalgia	TESSER	JOHN	PHOENIX	AZ	\$98,689.97
TEXAS HEALTH RESEARCH AND TEXAS HEALTH RESEARCH AND	Edoxaban vs. Warfarin in Subjects Undergoing	CHEIRIF TAKATA	JORGE	DALLAS	TX TX	\$8,750.59 \$2,880.00
	Edoxaban vs. Warfarin in Subjects Undergoing	TAKATA NORTH	THEODORE JAMES	FORT WORTH WINSTON SALEM	TX NC	\$2,880.00 \$11,228.48
						,∠∠∠0.40
THE CENTER FOR CLINICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia				MD	\$62,358.00
	Treatment of Pain Associated With Fibromyalgia An Open-Label Extension Study of DS-5565 for 52 Weeks in	BARAF CHAPPEL	HERBERT CHRISTOPHER	WHEATON KISSIMMEE	MD FL	\$62,358.00 \$131,321.80
THE CENTER FOR CLINICAL RESEARCH THE CENTER FOR RHEUMATOLOGY AND BONE RESEARCH		BARAF	HERBERT	WHEATON		

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
THE CHILDREN'S HOSPITAL OF PHILADELPHIA	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	KATZ	LORRAINE	PHILADELPHIA	PA	\$15,464.12
THE CHILDREN'S HOSPITAL OF PHILADELPHIA	Phase 1 Pediatric PKPD Study	ROSSANO	JOSEPH	PHILADELPHIA	PA	\$17,404.79
THE CHILDREN'S HOSPITAL RESEARCH INSTITUTE	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	KELSEY	MEGAN	AURORA	со	\$500.00
THE CHILDREN'S HOSPITAL RESEARCH INSTITUTE	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	KELSEY	MEGAN	AURORA	со	\$27,237.36
THE CURATORS OF THE UNIVERSITY OF MISSOURI THE CURATORS OF THE UNIVERSITY OF MISSOURI	Study to Evaluate the Efficacy, Safety, and Study to Evaluate the Efficacy, Safety, and	ACUFF KUHNS	MICHAEL CRAIG	COLUMBIA LAKEWAY	MO TX	\$12,819.46 \$1,734.37
THE CURATORS OF THE UNIVERSITY OF MISSOURI THE CURATORS OF THE UNIVERSITY OF MISSOURI	Study to Evaluate the Efficacy, Safety, and	REINSEL	THOMAS	COLUMBIA	MO	\$3,344.14
THE JOHNS HOPKINS UNIVERSITY	DU176b-D-U311	STREIFF	MICHAEL	BALTIMORE	MD	\$57.90
THE MEDICAL COLLEGE OF WISCONSIN INC.	Study to Evaluate the Efficacy, Safety, and	MAIMAN	DENNIS	MILWAUKEE	WI	\$11,365.86
THE MEDICAL RESEARCH NETWORK LLC	Treatment of Pain Associated With Fibromyalgia	BLATT	KYRA	NEW YORK	NY	\$13,265.82
THE OHIO STATE UNIVERSITY	An Open-Label Extension Study of DS-5565 for 52 Weeks in	HACKSHAW	KEVIN	COLUMBUS	OH	\$8,000.00
THE OHIO STATE UNIVERSITY THE OHIO STATE UNIVERSITY	Edoxaban Cancer VTE	WANG OTTERSON	TZU-FEI GREGORY	COLUMBUS	ОН ОН	\$12,679.20 \$11,797.00
THE OHIO STATE UNIVERSITY THE OHIO STATE UNIVERSITY	Study of Patritumab in Combination With Study of Treatment of Pain Associated With Fibromyalgia	HACKSHAW	KEVIN	COLUMBUS	ОН	\$8,000.00
THE PRESIDENTAND DIRECTORS OF GEORGETOWN	Study of Tivantinib in Subjects With Inoperable	HE	AIWU	WASHINGTON	DC	\$25,730.91
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	Study of Tivantinib in Subjects With Inoperable	FINN	RICHARD	LOS ANGELES	CA	\$48,731.40
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	Study to Evaluate the Efficacy, Safety, and	KIM	KEE	SACRAMENTO	CA	\$11,987.24
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	TIVANTINIB	GOLDMAN	JONATHAN	SANTA MONICA	CA	\$106.20
THE REGENTS OF UNIVERSITY OF CALIFORNIA IRVINE	Study of Patritumab in Combination With Study of	OU	SAI HONG	ORANGE	CA	\$13,115.00
	Study to Evaluate the Efficacy, Safety, and	GALLER	ROBERT	EAST SETAUKET	NY	\$736.82
THE UNIVERSITY OF ARIZONA THE UNIVERSITY OF ARIZONA	Study of Tivantinib in Subjects With Inoperable Study to Evaluate the Efficacy, Safety, and	PATEL ANTON	HITENDRA REIN	KANSAS CITY TUCSON	MO AZ	\$73,239.88 \$4,931.34
THE UNIVERSITY OF CHICAGO	Study of Tivantinib in Subjects With Inoperable	CATENACCI	DANIEL	CHICAGO	IL	\$4,000.00
	DU176b-E-U210	PASCARELLA	LUIGI	IOWA CITY	IA	\$3,646.00
THE UNIVERSITY OF IOWA	Study to Evaluate the Efficacy, Safety, and	HITCHON	PATRICK	IOWA CITY	IA	\$6,527.72
THEBAUD, ADLY	An Open-Label Extension Study of DS-5565 for 52 Weeks in	THEBAUD	ADLY	SANFORD	FL	\$5,000.00
THEBAUD, ADLY	Treatment of Pain Associated With Fibromyalgia	THEBAUD	ADLY	SANFORD	FL	\$49,531.89
THORNTON, KATHERINE	Neoadjuvant and Personalized Adaptive Novel Agents to					\$5,070.61
THORNTON, KATHERINE	PLX3397 Phase 3 Study for Pigmented Villonodular				↓ ↓	\$1,383.87
THORNTON, KATHERINE	Study to Evaluate the Safety, Tolerability and	THUDAAN	LOUISE		OK	\$6,010.96
THURMAN, LOUISE THURMAN, LOUISE	An Open-Label Extension Study of DS-5565 for 52 Weeks in Treatment of Pain Associated With Fibromyalgia	THURMAN THURMAN	LOUISE	OKLAHOMA CITY OKLAHOMA CITY	ОК ОК	\$37,213.90 \$158,130.10
TIDEWATER INTEGRATED MEDICAL RESEARCH	Treatment of Pain Associated With Fibromyalgia	HAASE	GREGORY	VIRGINIA BEACH	VA	\$158,130.10 \$10,650.00
TODD J SWICK MD PA	Treatment of Pain Associated With Fibromyalgia	SWICK	TODD	HOUSTON	TX	\$6,407.24
TORRES, GUSTAVO	Treatment of Pain Associated With Fibromyalgia	TORRES	GUSTAVO	HIALEAH	FL	\$51,383.58
TRAER, ELIE	(QuANTUM-R): An Open-label Study of Quizartinib	TRAER	ELIE	PORTLAND	OR	\$23,075.98
TRANSLATIONAL RESEARCH MANAGEMENT LLC	Study of Erlotinib With or Without Investigational Drug (U3	EBRAHIMI	BEHNAM	POMONA	CA	\$3,092.51
TRANSLATIONAL RESEARCH MANAGEMENT LLC	Study of Erlotinib With or Without Investigational Drug (U3		MICHAEL	SCOTTSDALE	AZ	\$3,211.45
TRANSLATIONAL RESEARCH MANAGEMENT LLC	Study of Erlotinib With or Without Investigational Drug (U3		DEVINDER	GLENDALE	AZ	\$9,029.00
TRANSLATIONAL RESEARCH MANAGEMENT LLC TRENOR, CAMERON	Study of Patritumab in Combination With Study of Phase 1 Pediatric PKPD Study	ADOO	CLARENCE	GLENDALE	AZ	\$1,750.00 \$51.92
TRINITY CLINICAL RESEARCH LLC	Phase 1 Pediatric PKPD Study	LEE	MARCUS	TULLAHOMA	TN	\$5,233.80
	An Open-Label Extension Study of DS-5565 for 52 Weeks in	DIRI	ERDAL	MINOT	ND	\$17,298.94
TRINITY MEDICAL GROUP	Treatment of Pain Associated With Fibromyalgia	DIRI	ERDAL	MINOT	ND	\$62,609.89
TRUMAN MEDICAL CENTER W GOLD CLINIC	Study to Evaluate the Efficacy, Safety, and	GIANINO	JOHN	KANSAS CITY	MO	\$1,000.00
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW	A Phase 3, Randomized, Double-Blind Study of Tivantinib	SCHWARTZ	LAWRENCE	NEW YORK	NY	\$612.50
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	Study of Tivantinib in Subjects With Inoperable	DAMJANOV	NEVENA	PHILADELPHIA	PA	\$114,978.02
TUFTS MEDICAL CENTER		VLAD	STEVEN	BOSTON	MA	\$14,000.00
TUFTS MEDICAL CENTER TURNER, MARK	An Open-Label Extension Study of DS-5565 for 52 Weeks in	TURNER	MARK	MERIDIAN	ID	\$1,180.00 \$3,500.00
TURNER, MARK	Treatment of Pain Associated With Fibromyalgia	TURNER	MARK	MERIDIAN	ID	\$36,610.52
TYLER CARDIOVASCULAR CONSULTANTS PA	Edoxaban vs. Warfarin in Subjects Undergoing	TORRES-HEISECKE	RAUL	TYLER	TX	\$5,602.40
TYLER CARDIOVASCULAR CONSULTNTS	Edoxaban vs. Warfarin in Subjects Undergoing	TORRES-HEISECKE	RAUL	TYLER	тх	\$10,063.30
TYLER CARDIOVASCULAR CONSULTNTS	TC00002989	TORRES-HEISECKE	RAUL	TYLER	ТΧ	\$53.70
UC HEALTHCARE SYSTEM		ARNOLD	LESLEY	CINCINNATI	OH	\$100.00
UC REGENTS	PLX108-10	CHMIELOWSKI	BARTOSZ	LOS ANGELES	CA	\$19,935.00
UCLA UCLA	ARQ197 Study of Tivantinib in Subjects With Inoperable	FINN FINN	RICHARD	LOS ANGELES LOS ANGELES	CA CA	\$457.57 \$532.86
UENO, NAOTO	A Clinical Trial Using Patritumab or Placebo in Combination	T IININ	RICHARD	LOS ANGLELS	CA	\$89.80
	Phase 1 Pediatric PKPD Study	SULLIVAN	JANICE	LOUISVILLE	кү	\$750.00
UNIVERISTY OF NEBRASKA MEDICAL CENTER	ARQ 197 Plus Study of Erlotinib With or Without	KESSINGER	MARGARET	OMAHA	NE	\$1,119.60
UNIVERISTY OF NEBRASKA MEDICAL CENTER	TIVANTINIB	KESSINGER	MARGARET	OMAHA	NE	\$153.36
UNIVERITY OF WASHINGTON	PLX108-10	LOGGERS	ELIZABETH	SEATTLE	WA	\$11,350.00
UNIVERSITY AZ CNCR CENTER NORTH CAMPUS	ARQ197	PATEL	HITENDRA	KANSAS CITY	MO	\$318.15
UNIVERSITY AZ CNCR CENTER NORTH CAMPUS	Study of Tivantinib in Subjects With Inoperable Colesevelam Pediatric Type 2 Diabetes Mellitus Study	PATEL LITTLEJOHN	HITENDRA	KANSAS CITY	MO	\$422.44 \$10.607.94
UNIVERSITY CHICAGO MEDICAL NRSRGRY UNIVERSITY CHICAGO MEDICAL NRSRGRY	Colesevelam Pediatric Type 2 Diabetes Mellitus Study DS8273-A-U101	LITTLEJOHN MAITLAND	ELIZABETH MICHAEL	BURR RIDGE CHICAGO	IL IL	\$10,607.94 \$76,091.80
	Open-label Study of DS-8273a to Assess Its Safety and	MAITLAND	MICHAEL	CHICAGO	IL	\$10,782.00
UNIVERSITY CHICAGO MEDICAL NISNGRY	Study of Patritumab in Combination With Study of	SALGIA	RAVI	BURR RIDGE	IL	\$18,150.00
UNIVERSITI CHICAGO MEDICAE INISINGINI					OH	\$22,858.64
UNIVERSITY HOSPITALS CASE MEDICAL CENTER -	Phase 1 Pediatric PKPD Study	AHUJA	SANJAY	CLEVELAND		6420.42
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY	PLX108-10	WILKY	BREELYN	MIAMI	FL	\$420.12
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM -	PLX108-10 DS8273-A-U101	WILKY FORERO-TORRES	BREELYN ANDRES	MIAMI BIRMINGHAM	FL AL	\$93,941.33
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM -	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and	WILKY FORERO-TORRES FORERO-TORRES	BREELYN ANDRES ANDRES	MIAMI BIRMINGHAM BIRMINGHAM	FL AL AL	\$93,941.33 \$27,868.52
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study	WILKY FORERO-TORRES FORERO-TORRES CHIN	BREELYN ANDRES ANDRES CINDY	MIAMI BIRMINGHAM BIRMINGHAM TUCSON	FL AL AL AZ	\$93,941.33 \$27,868.52 \$3,204.00
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARKANSAS MEDICAL CENTER	PLX108-10 DS8273 A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG	BREELYN ANDRES ANDRES CINDY ZHIFU	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK	FL AL AL AZ AR	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study	WILKY FORERO-TORRES FORERO-TORRES CHIN	BREELYN ANDRES ANDRES CINDY ZHIFU SAI HONG	MIAMI BIRMINGHAM BIRMINGHAM TUCSON	FL AL AL AZ	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG DU	BREELYN ANDRES ANDRES CINDY ZHIFU	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE	FL AL AL AZ AR CA	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA AVIS MEDICAL CENTER	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS2248-A-U101 DS6051-A-U101 DU176b-D-U311	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU OU WUN	BREELYN ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG THEODORE	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO	FL AL AL AZ AR CA CA CA CA CA	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA A DAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA LOS ANGELES	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS6051-A-U101 DS248-A-U101 DS176b-D-U311 Phase 1 Pediatric PKPD Study	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU OU WUN KEMPERT	BREELYN ANDRES ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG THEODORE PAMELA	MIAMI BIRMINGHAM BIRMINGHAM TUCSON UTTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA	FL AL AZ AR CA	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT DEPARTMENT OF PEDIATRICS UNIVERSITY OF ALABAMASAS MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA J DAVIS MEDICAL CENTER	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS2248-A-U101 DS6051-A-U101 DU176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU OU WUN KEMPERT BADHWAR	BREELYN ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG PAMELA NITISH	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO	FL AL AL AZ AR CA	\$93,941.33 \$27,868.52 \$3,204.00 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00 \$222,67
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIANASA MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA JON'S MEDICAL CENTER UNIVERSITY OF CALIFORNIA LOS ANGELES UNIVERSITY OF CALIFORNIA LOS ANGELES UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS5051-A-U101 DU176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102	WILKY FORERO-TORRES CHIN XIANG OU OU OU OU WUN KEMPERT BADHWAR OLIN	BREELYN ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG PAMELA NITISH REBECCA	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO	FL AL AL AZ AR CA CA CA CA CA CA CA CA CA	\$93,941.33 \$27,868.52 \$3,204.00 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00 \$222.67 \$174,293.55
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA JAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA JAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA JAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS6051-A-U101 DJ176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Twantinib in Subjects With Inoperable	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU WUN KEMPERT BADHWAR OLIN	BREELYN ANDRES ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG THEODORE PAMELA NITISH REBECCA STEPHEN	MIAMI BIRMINGHAM BIRMINGHAM TUCSON UTTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO WESTWOOD	FL AL AL AZ AR CA CA CA CA CA CA CA CA CA CA CA CA CA	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00 \$272.67 \$174,293.55 \$210.60
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA IN AVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA LOS ANGELES UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF CHCLAGO HOSPITAL UNIVERSITY OF CICIONNATI PHYSICIANS COMPANY LLC	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS5248-A-U101 DJ176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Tivantinib in Subjects With Inoperable Treatment of Pain Associated With Fibromyalgia	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU WUN KEMPERT BADHWAR OLIN WILLIAMSON ARNOLD	BREELYN ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG SAI HONG PAMELA NITISH REBECCA STEPHEN LESLEY	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO SAN FRANCISCO WESTWOOD CINCINNATI	FL AL AL AL AL AZ AR CA CCA CCA CCA CCA CCA CCA CCA CCA C	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$272.67 \$12,454.00 \$222.67 \$174,293.55 \$210.60 \$62,637.84
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONAS MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA JON SMEDICAL CENTER UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS2248-A-U101 DS248-A-U101 DU176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Tivantinib in Subjects With Inoperable Treatment of Pain Associated With Fibromyalgia Phase 1 Pediatric PKPD Study	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU OU BADHWAR OLIN WILLIAMSON ARNOLD WAANG	BREELYN ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG THEODORE PAMELA NITISH REBECCA STEPHEN LESLEY MICHAEL	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO WESTWOOD CINCINNATI AURORA	FL AL AL AZ AZ AZ AZ AZ CA CCA CCA CCA CCA CCA C	\$93,941.33 \$77,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00 \$272.67 \$174,293.55 \$210.60 \$62,637.84 \$13,387.50
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI INCIROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA I DAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA I DAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC UNIVERSITY OF CICOLORADO DENVER UNIVERSITY OF FLORIDA	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS5248-A-U101 DJ176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Tivantinib in Subjects With Inoperable Treatment of Pain Associated With Fibromyalgia	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU WUN KEMPERT BADHWAR OLIN WILLIAMSON ARNOLD	BREELYN ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG SAI HONG PAMELA NITISH REBECCA STEPHEN LESLEY	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO SAN FRANCISCO WESTWOOD CINCINNATI	FL AL AL AL AL AZ AR CA CCA CCA CCA CCA CCA CCA CCA CCA C	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00 \$272.67 \$174,293.55 \$210.60 \$62,637.84
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI INCIROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA I DAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA I DAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC UNIVERSITY OF CICOLORADO DENVER UNIVERSITY OF FLORIDA	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS6051-A-U101 DJ176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Twantinib in Subjects With Inoperable Treatment of Pain Associated With Fibromyalgia Phase 1 Pediatric PKPD Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU OU BADHWAR OLIN WILLIAMSON ARNOLD WANG SILVERSTEIN	BREELYN ANDRES ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG THEODORE PAMELA NITISH REBECCA STEPHEN LESLEY MICHAEL JANET	MIAMI BIRMINGHAM BIRMINGHAM TUCSON UTTLE ROCK ORANGE ORANGE ORANGE SARRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO WESTWOOD CINCINNATI AURORA GAINESVILLE	FL AL AL AL AL AZ AL AZ AR CA	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$75.90 \$12,454.00 \$272.67 \$174,293.55 \$210.60 \$62,637.84 \$13,387.50 \$28,513.62
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI INCUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA DAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA DAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA JANY FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF COLORADO DENVER UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS6051-A-U101 DJ176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Trvantinib in Subjects With Inoperable Treatment of Pain Associated With Fibromyalgia Phase 1 Pediatric PKPD Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Study of Tivantinib in Subjects With Inoperable Study of Tivantinib in Subjects With Inoperable	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU WUN KEMPERT BADHWAR OLINN WILLIAMSON ARNOLD WILLIAMSON ARNOLD	BREELYN ANDRES ANDRES CINDY ZHIFU SAI HONG SEVENDER PAMELA NITISH REBECCA STEPHEN LESLEY MICHAEL JANET RONIEL STEPHEN PAUL	MIAMI BIRMINGHAM BIRMINGHAM TUCSON UTTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO WESTWOOD CINCINNATI AURORA GAINESVILLE GAINESVILLE WESTWOOD	FL AL AZ AZ CA CO FL KS	\$93,941.33 \$27,868.25 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$27.67 \$174,293.55 \$210.60 \$62,637.84 \$13,387.50 \$28,513.62 \$20,311.88 \$55,101.80 \$55,284.46
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA JAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA JAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA JAVIS MEDICAL CENTER UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF CICONADO DENVER UNIVERSITY OF CICOLORADO DENVER UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA KUMC Research Institute KUMC Research Institute	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS2248-A-U101 DD176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 DS3032-A-U102 DS3032-A-U102 DS3032-A-U102 DS3032-A-U102 DS3032-A-U102 DS3032-A-U102 Colesevelam Pediatric TyPe 2 Diabetes Mellitus Study Study of Tivantinib in Subjects With Inoperable Study to Evaluate the Efficacy, Safety, and DS1040-A-U103	WILKY FORERO-TORRES CHIN XIANG OU OU OU OU WUN KEMPERT BADHWAR OLIN WULLIAMSON ARNOLD WANG SILVERSTEIN CABRERA WILLIAMSON ARNOLD LIU	BREELYN ANDRES ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG PAMELA NITISH REBECCA STEPHEN LESLEY MICHAEL JANET RONIEL STEPHEN PAMELA	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO WESTWOOD CINCINNATI AURORA GAINESVILLE GAINESVILLE GAINESVILLE UVESTWOOD	FL AL AZ AZ CA KS	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,5567.15 \$38,279.95 \$57.90 \$12,454.00 \$272.67 \$174,293.55 \$210.60 \$62,637.84 \$13,387.50 \$28,513.62 \$20,311.88 \$51,101.80 \$5,284.46 \$5,284.46 \$266.64
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIZONAS MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA JOS MEDICAL CENTER UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA KUMC Research Institute KUMC Research Institute UNIVERSITY OF MIAMI	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS2248-A-U101 DS0551-A-U101 DU176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Tivantinib in Subjects With Inoperable Treatment of Pain Associated With Fibromyalgia Phase 1 Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Study of Tivantinib in Subjects With Inoperable Study to Evaluate the Efficacy, Safety, and DS100-A-U103	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU OU WUN KEMPERT BADHWAR OLIN WILLIAMSON ARNOLD WILVERSTEIN CABRERA WILLIAMSON ARNOLD LIU WILKY	BREELYN ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG SAI HONG MICHAG PAMELA NITISH REBECCA STEPHEN LESLEY MICHAEL JANET RONIEL STEPHEN PAUL WEI BREELYN	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO SAN FRANCISCO GAINESVILLE GAINESVILLE WESTWOOD KANSAS CITY LOUISVILLE MIAMI	FL AL AZ AR CA CA	\$93,941.33 \$27,868.2 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00 \$272.67 \$174,293.55 \$210.60 \$26,637.84 \$13,387.50 \$28,513.62 \$20,311.88 \$51,101.80 \$5,284.46 \$266.64 \$16,386.67
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF CALIFORNIA - IRVINE UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA JAVIS AMBELCAL CENTER UNIVERSITY OF CALIFORNIA JAVIS AMBELCAL CENTER UNIVERSITY OF CALIFORNIA JAVIS ANGELES UNIVERSITY OF CALIFORNIA JAVIS ANGLOCO - HELEN UNIVERSITY OF CALIFORNIA SAN FRANCISCO - HELEN UNIVERSITY OF COLORADO DENVER UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA KUMC Research Institute KUMC Research Institute UNIVERSITY OF MIAMI UNIVERSITY OF MIAMI	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-0311 DS6051-A-U101 DS6051-A-U101 DJ176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Tivantinib in Subjects With Inoperable Treatment of Pain Associated With Fibromyalgia Phase 1 Pediatric PKPD Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Study of Tivantinib in Subjects With Inoperable Study to Evaluate the Efficacy, Safety, and DS1040-A-U103 PLX108-10 ARQ197	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU WUN KEMPERT BADHWAR OLIN WILLIAMSON ARNOLD WILLIAMSON ARNOLD LIU WILLY GREENQ	BREELYN ANDRES ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG PAMELA PAMELA REBECCA STEPHEN LESLEY MICHAEL JANET RONIEL STEPHEN PAUL WEI BREELYN EDWARD	MIAMI BIRMINGHAM BIRMINGHAM TUCSON UTTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO WESTWOOD CINCINNATI AURORA GAINESVILLE GAINESVILLE GAINESVILLE MIAMI MINNEAPOLIS	FL AL AZ AZ CA CCA CA CO FL MN	\$93,941.33 \$27,868.25 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00 \$272.67 \$174,293.55 \$210.60 \$62,637.84 \$13,387.50 \$28,513.62 \$20,311.88 \$51,101.80 \$55,284.46 \$55,284.46 \$55,284.46 \$56,386.67 \$55.97
UNIVERSITY HOSPITALS CASE MEDICAL CENTER - UNIVERSITY MIAMI NEUROLOGY UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ALABAMA AT BIRMINGHAM - UNIVERSITY OF ARIZONA - DEPARTMENT OF PEDIATRICS UNIVERSITY OF ARIXANSA MEDICAL CENTER UNIVERSITY OF CALIFORNIA - IRVINE MEDICAL CENTER UNIVERSITY OF CALIFORNIA AN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CALIFORNIA SAN FRANCISCO UNIVERSITY OF CINCINATI PHYSICIANS COMPANY LLC UNIVERSITY OF CINCINATI PHYSICIANS COMPANY LLC UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA UNIVERSITY OF FLORIDA KUMC Research Institute KUMC Research Institute UNIVERSITY OF MIAMI	PLX108-10 DS8273-A-U101 Open-label Study of DS-8273a to Assess Its Safety and Colesevelam Pediatric Type 2 Diabetes Mellitus Study DU176b-D-U311 DS6051-A-U101 DS2248-A-U101 DS0551-A-U101 DU176b-D-U311 Phase 1 Pediatric PKPD Study Edoxaban vs. Warfarin in Subjects Undergoing DS3032-A-U102 Study of Tivantinib in Subjects With Inoperable Treatment of Pain Associated With Fibromyalgia Phase 1 Pediatric Type 2 Diabetes Mellitus Study Colesevelam Pediatric Type 2 Diabetes Mellitus Study Study of Tivantinib in Subjects With Inoperable Study to Evaluate the Efficacy, Safety, and DS100-A-U103	WILKY FORERO-TORRES FORERO-TORRES CHIN XIANG OU OU OU OU WUN KEMPERT BADHWAR OLIN WILLIAMSON ARNOLD WILVERSTEIN CABRERA WILLIAMSON ARNOLD LIU WILKY	BREELYN ANDRES CINDY ZHIFU SAI HONG SAI HONG SAI HONG SAI HONG SAI HONG MICHAG PAMELA NITISH REBECCA STEPHEN LESLEY MICHAEL JANET RONIEL STEPHEN PAUL WEI BREELYN	MIAMI BIRMINGHAM BIRMINGHAM TUCSON LITTLE ROCK ORANGE ORANGE ORANGE SACRAMENTO LOMA LINDA SAN FRANCISCO SAN FRANCISCO SAN FRANCISCO GAINESVILLE GAINESVILLE WESTWOOD KANSAS CITY LOUISVILLE MIAMI	FL AL AZ AR CA CA	\$93,941.33 \$27,868.52 \$3,204.00 \$57.90 \$22,142.98 \$5,567.15 \$38,279.95 \$57.90 \$12,454.00 \$272.67 \$174,293.55 \$210.60 \$26,637.84 \$13,387.50 \$28,513.62 \$20,311.88 \$51,101.80 \$5,284.46 \$266.64 \$16,386.67

D	Stude Name	Principal Investigator /	Principal Investigator /	City of PI / Lead	State of PI / Lead	Total
Payee	Study Name	Lead Researcher Last Name	Lead Researcher First Name	Researcher	Lead Researcher	Iotal
UNIVERSITY OF SOUTH FLORIDA DIABETES CENTER	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	RODRIGUEZ	HENRY	ТАМРА	FL	\$13,506.00
UNIVERSITY OF SOUTHERN CALIFORNIA	An Open-Label Extension Study of DS-5565 for 52 Weeks in		SAID	LOS ANGELES	CA	\$55,610.30
UNIVERSITY OF SOUTHERN CALIFORNIA	PLX108-10	HU	JAMES	LOS ANGELES	CA	\$20,655.00
UNIVERSITY OF SOUTHERN CALIFORNIA	Study to Evaluate the Efficacy, Safety, and	HSIEH	PATRICK	LOS ANGELES	CA	\$35,080.65
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	LYNCH	JANE	SAN ANTONIO	TX	\$20,461.00
UNIVERSITY OF UTAH	Phase 1 Pediatric PKPD Study	SPIGARELLI	MICHAEL	SALT LAKE CITY	UT	\$5,320.00
UNIVERSITY OF UTAH	PLX108-10	WRIGHT	JENNIFER	SALT LAKE CITY	UT	\$16,820.00
UNIVERSITY TX MD ANDRSN CANCR CENTER	DU176b-D-U311	ROJAS-HERNANDEZ	CRISTHIAM	HOUSTON	TX	\$57.90
UNIVERSITY TX MD ANDRSN CANCR CENTER	PLX108-10	RAVI	VINOD	HOUSTON	тх	\$410.50
UPMC CANCER PAVILLION	PLX108-10	TAWBI	HUSSEIN	PITTSBURGH	PA	\$410.50
USC NORRIS COMPREHENSIVE CANCER CENTER	ARQ197-A-U160	EL-KHOUEIRY	ANTHONY	LOS ANGELES	CA	\$144,261.00
USC NORRIS COMPREHENSIVE CANCER CENTER	Pharmacokinetics of Tivantinib in Subjects With Advanced	EL-KHOUEIRY	ANTHONY	LOS ANGELES	CA	\$18,713,10
VALOR, ELENA	Treatment of Pain Associated With Fibromyalgia	VALOR	ELENA	MIAMI	FL	\$103,738.74
VAN DE RIJN, MATTHIJS	Neoadjuvant and Personalized Adaptive Novel Agents to				r -	\$2,453.88
VAN TINE, BRIAN	PLX3397 Phase 3 Study for Pigmented Villonodular					\$1,576.43
VANDERBILT - INGRAM CANCER CENTER	PLX108-10	KEEDY	VICKI	NASHVILLE	TN	\$254.45
VANDERBILT UNIVERSITY MEDICAL CENTER	PLX108-10	KEEDY	VICKI	NASHVILLE	TN	\$20,280,00
VASCULAR AND INTERVENTIONAL SPECIALTIES OF	DU176b-E-U210	RAZAVI	MAHMOOD	ORANGE	CA	\$8,840.65
VASQUEZ, ALBERTO	An Open-Label Extension Study of DS-5565 for 52 Weeks in	VASQUEZ	ALBERTO	ST PETERSBURG	FL	\$4,500.00
VATAKIS, NICK	Treatment of Pain Associated With Fibromyalgia	VATAKIS	NICK	NEW YORK	NY	\$50,506.84
VENTRE, PETER	An Open-Label Extension Study of DS-5565 for 52 Weeks in	VENTRE	PETER	OAKLAND PARK	FL	\$7,919.41
VIRGINIA COMMONWEALTH UNIVERSITY	Edoxaban vs. Warfarin in Subjects Undergoing	ELLENBOGEN	KENNETH	RICHMOND	VA	\$4,766.35
VLAD. STEVEN	Treatment of Pain Associated With Fibromyalgia	VLAD	STEVEN	BOSTON	MA	\$33,621.71
VOLUNTEER RESEARCH GROUP LLC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	SMITH	WILLIAM	NEW ORLEANS	LA	\$3.050.00
VOLUNTEER RESEARCH GROUP LLC	Treatment of Pain Associated With Fibromyalgia	SMITH	WILLIAM	NEW ORLEANS	LA	\$12,619.56
VOLUNTEER RESEARCH GROUP LLC	Treatment of Fain Associated with Horomyaigia	SMITH	WILLIAM	NEW ORLEANS	LA	\$1,125.00
WAGNER, ANDREW	PLX3397 Phase 3 Study for Pigmented Villonodular	5	WILLI/ WI	HEN ONLES IND	51	\$695.79
WAGNER, ANDREW	Study to Evaluate the Safety, Tolerability and			-		\$8,168.65
WAKE FOREST UNIVERSITY HEALTH	Study to Evaluate the Efficacy, Safety, and	HSU	WESLEY	WINSTON SALEM	NC	\$750.00
WAKE RESEARCH ASSOCIATION	Study to Evaluate the Emeacy, Salety, and	HARPER	WAYNE	RALEIGH	NC	\$13,879.48
WAKEMED CHILDREN'S DIABETES AND ENDOCRINOLOG	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	LAGARDE	WILLIAM	CHAPEL HILL	NC	\$11,655.00
WAKEMED CHIEDREN'S DIABETES AND ENDOCRINOLOG	DU176b-E-U210	ADAMS	GEORGE	GARNER	NC	\$12,150.50
WAKEMED RALEIGH CAMPUS	Edoxaban in Peripheral Arterial Disease ePAD	ADAMS	GEORGE	GARNER	NC	\$3,000.00
WALTMAN, CLAIRE	An Open-Label Extension Study of DS-5565 for 52 Weeks in	WALTMAN	CLAIRE	SEATTLE	WA	\$7,705.80
WANG, EUNICE	Quizartinib With Standard of Care Chemotherapy and as	WALIWAN	CEAINE	JEATTEE	WA	\$11.637.52
WARD, KATHLEEN	An Open-Label Extension Study of DS-5565 for 52 Weeks in	WARD	KATHLEEN	LA GRANGE	u	\$13,194.68
WASHINTON UNIVERSITY ORTHOPDICS	PLX108-10	VAN TINE	BRIAN	SAINT PETERS	MO	\$21,041.00
WASHINTON UNIVERSITY ORTHOPDICS	Study of Patritumab in Combination With Study of	WAQAR	SAIAMA	SAINT LOUIS	MO	\$23,907.50
WASHINTON UNIVERSITY ORTHOPDICS	Study to Evaluate the Efficacy, Safety, and	RAY	WILSON	SAINT LOUIS	MO	\$750.00
WASHINTON UNIVERSITY ORTHOPPICS	U3-1287-A-U104 PET	LOCKHART	ALBERT	SAINT LOUIS	MO	\$66.588.25
WELLS INSTITUTE	An Open-Label Extension Study of DS-5565 for 52 Weeks in	Thompson-Hargrave	Letitia	Dayton	ОН	\$11,025.00
WELLS INSTITUTE	An Open-Laber Extension Study of DS-5505 for 52 weeks in	Thompson-Hargrave	Letitia	Dayton	ОН	\$2,500.00
WENATCHEE VALLEY HOSPITAL & CLINIC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	KASTER	STEVEN	WENATCHEE	WA	\$43,183.23
WENATCHEE VALLET HOSTITAL & CLINIC	An Open-Laber Extension Study of DS-5505 for 52 weeks in	COHEN GADOL	SHARIAR	THOUSAND OAKS	CA	\$4,000.00
WICHITA FALLS HEART CLINIC	Edoxaban vs. Warfarin in Subjects Undergoing	GANESHRAM	VEDAMPATTU	WICHITA FALLS	ТХ	\$9,764.99
WIEDUWILT, MATTHEW	(QuANTUM-R): An Open-label Study of Quizartinib	WIEDUWILT	MATTHEW	LA JOLLA	CA	\$22,932.00
WILKY, BREELYN	PLX3397 Phase 3 Study for Pigmented Villonodular	WIEDOWIEI	WATTIEW	LAJOLLA	CA	\$1,704.31
WILLIAMS, HAYES	An Open-Label Extension Study of DS-5565 for 52 Weeks in	\A/II I A A A S	HAYES	VESTAVIA	AL	\$13,928.48
WILLIAMS, HAYES	Treatment of Pain Associated With Fibromyalgia	WILLIAMS	HAYES	VESTAVIA	AL	\$67,177.34
WOLFSON, ERIC	An Open-Label Extension Study of DS-5565 for 52 Weeks in	WOLFSON	ERIC	LAS VEGAS	NV	\$38,686.65
WOMBOLT, DUANE	Treatment of Pain Associated With Fibromyalgia	WOMBOLT	DUANE	NORFOLK	VA	\$46,351.97
WOYSHVILLE, MARK	Treatment of Pain Associated With Fibromyalgia	WOYSHVILLE	MARK	MIDDLEBURG HEIGHTS	OH	\$20,000.03
XENOSCIENCE INC.	reaction of Fain Associated With Fibroniyalgia	FLITMAN	STEPHEN	PHOENIX	AZ	\$20,000.03
Y & L ADVANCE HEALTH CARE INC.		TORRES CONSUEGRA	AURELIO	HIALEAH	AZ FL	\$5,566.60
YANG, JAY	(QuANTUM-R): An Open-label Study of Quizartinib	YANG	JAY	DETROIT	MI	\$4,000.00
YEAGER, ANDREW	(QuANTUM-R): An Open-label Study of Quizartinib (QuANTUM-R): An Open-label Study of Quizartinib	YEAGER	ANDREW	TUCSON	AZ	\$19,619.80 \$4,350.00
YEAGER, ANDREW YEH, IWEI	(Quanti Own). All Open-laber study of Quizartinib	TLAGER	ANDINEW	TUCSUN	m2	
YEH, IWEI YOUNG, DOUGLAS	An Open-Label Extension Study of DS-5565 for 52 Weeks in	VOLING	DOUGLAS	SACRAMENTO	CA	\$105.40 \$35,917.19
YOUNG, DOUGLAS YOUNG, DOUGLAS				SACRAMENTO	CA	\$35,917.19 \$175,151.32
	Treatment of Pain Associated With Fibromyalgia	YOUNG	DOUGLAS			
YOUNG, JOEL	Treatment of Pain Associated With Fibromyalgia	YOUNG	JOEL	ROCHESTER HILLS	MI	\$20,525.27
YURYEV, MICHAEL	An Open-Label Extension Study of DS-5565 for 52 Weeks in	YURYEV	MICHAEL	BROOKLYN	NY	\$9,061.38
YURYEV, MICHAEL ZEITLER, PHILLIP	Treatment of Pain Associated With Fibromyalgia	YURYEV	MICHAEL	BROOKLYN	NY	\$39,871.25
	Colesevelam Pediatric Type 2 Diabetes Mellitus Study	1	1	1	1	\$1,352.87